WO2019115771A1 - Système de nébuliseur, système de maintien, combinaison comprenant un système de nébuliseur et un système de maintien, et procédé d'administration d'aérosol - Google Patents

Système de nébuliseur, système de maintien, combinaison comprenant un système de nébuliseur et un système de maintien, et procédé d'administration d'aérosol Download PDF

Info

Publication number
WO2019115771A1
WO2019115771A1 PCT/EP2018/084968 EP2018084968W WO2019115771A1 WO 2019115771 A1 WO2019115771 A1 WO 2019115771A1 EP 2018084968 W EP2018084968 W EP 2018084968W WO 2019115771 A1 WO2019115771 A1 WO 2019115771A1
Authority
WO
WIPO (PCT)
Prior art keywords
nebuliser
connection
adapter
nasal
holding
Prior art date
Application number
PCT/EP2018/084968
Other languages
English (en)
Inventor
Thomas Gallem
Uwe Hetzer
Albert BUCHOLSKI
Stefanie LACHMAYR
Michael Neuner
Jan Pfrang
Markus Reinhart
Martin Schlun
Carolin STÖCKL
Andre VOIGT
Elisabeth WASNER
Original Assignee
Pari Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pari Pharma Gmbh filed Critical Pari Pharma Gmbh
Publication of WO2019115771A1 publication Critical patent/WO2019115771A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
    • A61M16/0816—Joints or connectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A61M16/147—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase the respiratory gas not passing through the liquid container
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A61M16/0666—Nasal cannulas or tubing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A61M16/0683—Holding devices therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
    • A61M16/0816—Joints or connectors
    • A61M16/0833—T- or Y-type connectors, e.g. Y-piece
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3368—Temperature
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/20—Flow characteristics having means for promoting or enhancing the flow, actively or passively
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/08—Supports for equipment
    • A61M2209/082—Mounting brackets, arm supports for equipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/08—Supports for equipment
    • A61M2209/084—Supporting bases, stands for equipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2240/00—Specially adapted for neonatal use
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B17/00—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups
    • B05B17/04—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups operating with special methods
    • B05B17/06—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups operating with special methods using ultrasonic or other kinds of vibrations
    • B05B17/0607—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups operating with special methods using ultrasonic or other kinds of vibrations generated by electrical means, e.g. piezoelectric transducers

Definitions

  • Nebuliser System Holding System, Combination Comprising Nebuliser System and Holding System, and
  • the present invention relates to a nebuliser system
  • the invention relates to a holding system for holding a nebuliser or a nebuliser system and to a combination comprising such a nebuliser system and such a holding system.
  • a nebuliser for assisted breathing devices such as continuous positive airway pressure (CPAP) devices
  • CPAP continuous positive airway pressure
  • the invention relates to a holding system for holding a nebuliser or a nebuliser system and to a combination comprising such a nebuliser system and such a holding system.
  • Nebulisers for assisted breathing devices such as continuous positive airway pressure (CPAP) devices, are well known in the art.
  • CPAP continuous positive airway pressure
  • WO 2005/048982 A2 discloses such a nebuliser.
  • This nebuliser comprises a body having a first connection that comprises two connecting pieces for
  • the body comprises a second connection that again has two connecting pieces which are to be connected via a Y-piece and two tubes with a line leading to the patient.
  • Two separate flow channels that are connected via a connecting channel are formed in the body, one (first one) of which serves the flow of respiratory air from the air supply line to the patient and the other (second one) of which serves the flow of consumed air from the patient into the air exhaust line.
  • the nebulising device is coupled perpendicular, similar to a T-connection, to the first flow channel, with the aerosol being supplied in a direction perpendicular to the direction of flow in this first flow channel.
  • a problem associated with this design is on the one hand that owing to the non-return valve, an element is integrated in the air supply line, i.e. in the line that leads to the patient, which could have serious consequences should it malfunction .
  • inhalation device in which a nebulising device is arranged in a closed and bypassed housing.
  • the housing is disposed in a flow channel of the inhalator, which comprises a mouthpiece.
  • the nebulising device thereby nebulises in the direction of the mouthpiece.
  • dead volumes, flow resistance by the nebulising device as well as the filling thereof only play minor roles therein.
  • assisted breathing devices such as continuous positive airway pressure (CPAP) devices, however, the nebulisers must meet predefined criteria in this regard.
  • CPAP continuous positive airway pressure
  • EP-A-1 818 070 also discloses an inhalation therapy device having such a nebulisation direction, in this case, however, for premature babies.
  • the system requires the patient to be able to breathe on their own and is specifically adapted to the small line cross-sections with an inner diameter of between 2 mm and 3.5 mm for premature babies such that air may easily pass around the nebulisation device without flow resistance occurring. Furthermore, since the patient is able to breathe on their own, the system operates at a low
  • CPAP continuous positive airway pressure
  • nebuliser and patient has to be established and securely maintained over the respiration period.
  • a nebuliser system enabling efficient aerosol treatment with enhanced aerosol dosage efficiency and precision in an assisted breathing device, such as a continuous positive airway pressure (CPAP) device, in particular, for the treatment of children, especially neonates.
  • CPAP continuous positive airway pressure
  • the invention aims to provide a method of administering an aerosol to a patient, in
  • a further object of the present invention is to provide a holding system for holding a nebuliser or a nebuliser system which allows for efficient aerosol transport from the nebuliser to a patient, in particular, a child, especially a neonate, to be secured and reliably maintained.
  • the invention provides a nebuliser system comprising a nebuliser for assisted breathing devices, e.g., positive pressure assisted breathing devices, such continuous positive airway pressure (CPAP) devices.
  • the nebuliser comprises a body with a first connection for connecting the nebuliser to an assisted breathing device and a second connection for connecting the nebuliser to a patient, in particular, a child, especially a neonate.
  • the body forms a flow channel from the first connection to the second connection.
  • the nebuliser further comprises a nebulising device for
  • the nebulising device is arranged in the flow channel between the first connection and the second connection.
  • the nebuliser is configured for being adapted or connected to an oral and/or nasal communication element, such as nasal prongs, a nose mask, a face mask or a mouthpiece.
  • the oral and/or nasal communication element is configured for establishing fluid communication between the nebuliser and a patient's nose and/or mouth.
  • the first connection may be configured for connecting the nebuliser to the assisted breathing device directly or indirectly, e.g., via a tube.
  • the second connection may be configured for connecting the nebuliser to the oral and/or nasal communication element, such as the nasal prongs, a nose mask, a face mask or a mouthpiece, directly or indirectly, e.g., via an adapter.
  • the oral and/or nasal communication element is configured for establishing fluid communication between the nebuliser, in particular, the second connection, and the patient's nose and/or mouth.
  • the body of the nebuliser may form a single flow channel from the first connection to the second connection. Only one flow channel from the first connection to the second connection may be present. In this case, the body forms only one flow channel through which respiratory air flows from the first connection to the second connection during inhalation and consumed air flows from the second connection to the first connection during exhalation.
  • connection to the assisted breathing device such as a continuous positive airway pressure (CPAP) device
  • CPAP continuous positive airway pressure
  • the first connection may comprise or consist of a Y-piece for connection to the assisted breathing device.
  • the first CPAP continuous positive airway pressure
  • connection of the body of the nebuliser may be configured to be connected only to the air supply line.
  • a possible Y- piece may be arranged only downstream of the second
  • invention further comprises a nebulising device for
  • the liquid may be a liquid composition, such as an aqueous solution or an aqueous suspension, which preferably contains at least one active ingredient.
  • nebulising device refers to any aerosol generator or producer by means of which the liquid can be transformed into an aerosol form.
  • the nebulising device is arranged or disposed in the flow channel between the first connection and the second connection.
  • the nebuliser is configured for being adapted or connected to an oral and/or nasal communication element, such as the nasal prongs, a nose mask, a face mask or a mouthpiece.
  • an oral and/or nasal communication element such as the nasal prongs, a nose mask, a face mask or a mouthpiece.
  • the oral and/or nasal communication element is configured for
  • an aerosol generated by the nebulising device can be efficiently and reliably transported to the oral and/or nasal communication element, such as the nasal prongs, a nose mask, a face mask or a mouthpiece, via the flow channel and the second connection. In this way, aerosol losses in the
  • nebuliser are reduced, allowing for the generated aerosol to be administered to the patient with a high degree of
  • the invention provides a nebuliser system enabling efficient aerosol treatment with enhanced aerosol dosage precision in an assisted breathing device, such as a
  • CPAP continuous positive airway pressure
  • assisted breathing devices such as continuous positive airway pressure (CPAP) devices
  • CPAP continuous positive airway pressure
  • this bias flow which may be of the order of up to 30 1/min, normally flows directly into the air exhaust line from the air supply line.
  • the first connection of the body of the nebuliser preferably may be configured to connect with an air supply line coming from the assisted breathing device and an air exhaust line leading to the assisted breathing device in such a manner that a side- flow channel, i.e., a bypass, from the air supply line to the air exhaust line is formed on the side of the nebulising device that is opposite the second connection.
  • a side- flow channel i.e., a bypass
  • the air supply line and the air exhaust line of the assisted breathing device can thus be formed by a common element, such as a tube, that is divided into two sections.
  • This division may be formed either by a partition in the element, e.g., the tube, or for example by a coaxial tube, i.e., two tubes arranged one inside the other.
  • the common tube is to be connected to the first connection of the nebuliser.
  • the first connection and the common tube are thereby configured in such a manner that a bypass is formed between the nebulising device and the front face of the partition and/or of the inner tube of the coaxial tube, which is facing the
  • the bypass allows the bias flow to flow, outside of an inhalation cycle, directly into the air exhaust line from the air supply line without flushing any possibly nebulised liquid into the air exhaust line. Hence, the efficiency of the nebuliser system can be further improved.
  • the air supply line and the air exhaust line of the assisted breathing device may each be formed by a separate tube.
  • connection to the air supply line and a second connecting piece for connection to the air exhaust line each of which may be formed by a tube.
  • the bypass is then formed in the body itself between the first connecting piece and the second connecting piece and, outside of an inhalation cycle, allows a flow from the air supply line into the air exhaust line.
  • This arrangement further leads to a tilt-stable unit of the nebuliser being formed by the two connecting pieces and the opposite second connection.
  • the nebuliser system may be configured so that the mean lung deposition of an inhaled surfactant is at least 10%
  • the nebulising device may be configured to generate an aerosol, e.g., a liquid aerosol, with a particle size of less than 10 ym, preferably less than 5 ym, more preferably between 1 ym and 5 ym, and even more preferably between 2 ym and 4 ym.
  • an aerosol e.g., a liquid aerosol
  • the nebulising device may comprise a vibratable membrane and a vibrator.
  • the vibrator may be configured to vibrate the vibratable membrane so as to nebulise the liquid.
  • the nebulising device may comprise or be a vibrating membrane aerosol generator.
  • the nebulising device may comprise or be an electronic aerosol generator, e.g., a piezoelectrically driven aerosol generator, i.e., an aerosol generator driven by a piezoelectric element.
  • the vibrator of the nebulising device may comprise or consist of a piezoelectric element which is arranged for vibrating or oscillating the vibratable membrane.
  • the vibratable membrane is provided with a plurality of openings, in particular, micro openings, i.e., openings with diameters in the micrometer range, for nebulising the liquid.
  • the vibratable membrane is arranged substantially perpendicular to the direction of flow from the first
  • connection to the second connection so as to achieve
  • the membrane may also be arranged in the flow channel at a slight angle deviating by up to 45° from the perpendicular.
  • the openings of the membrane are preferably laser-drilled.
  • the laser-drilling process may include at least two laser drilling steps and, preferably, three laser drilling steps.
  • the membrane may have more than 1.500 openings to generate the aerosol, and preferably around 3.000 openings.
  • the membrane During the production of such a vibrating membrane, the membrane must be connected to the vibrator, actuator or oscillator that causes the membrane to vibrate (oscillate) , in particular, a piezo-electric vibrator, actuator or
  • This connection may be realised by attaching the membrane to a carrier or substrate, e.g., by gluing the membrane to the carrier or substrate using an adhesive.
  • the membrane and/or the carrier or substrate may be formed from stainless steel or another metallic material
  • the wall thickness of the membrane is thereby preferably less than 200 ym, more preferably between 25 ym and 200 ym and even more preferably between 50 ym and 120 ym.
  • the wall thickness of the carrier is preferably less than 500 ym, more preferably between 50 ym and 500 ym and even more preferably between 100 ym and 400 ym.
  • a vibrator, actuator or oscillator may be provided to cause at least the membrane for nebulising the fluid to oscillate, whereby the vibrator, actuator or oscillator may form the carrier or may be
  • the vibrator, actuator or oscillator may be arranged on the same side as the membrane or on an opposite second side of the carrier. Furthermore, the vibrator, actuator or oscillator is
  • a piezoceramic vibrator, actuator or oscillator in particular, a piezo vibrator, a piezo actuator or a piezo oscillator.
  • the wall thickness of the vibrator, actuator or oscillator is thereby of a comparable size and is preferably less than 500 ym, more preferably between 25 ym and 500 ym and even more preferably between 100 ym and 400 ym.
  • the carrier or substrate may be configured so as to have a substantially circular shape.
  • other shapes of the carrier or substrate such as an oval shape, are also possible.
  • the vibrator, actuator or oscillator may be configured so as to have a substantially annular shape, i.e., a ring shape with an opening in the centre.
  • a substantially annular shape i.e., a ring shape with an opening in the centre.
  • other shapes of the vibrator, actuator or oscillator such as an oval shape with an opening in the centre, are also possible.
  • the membrane may be arranged so as to be disposed at least partly within the opening of the vibrator, actuator or oscillator.
  • the nebulising device may comprise the carrier or substrate, the membrane, a housing, and the vibrator, actuator or oscillator.
  • the housing may be made of a plastic material.
  • the carrier or substrate may be at least partly received in and held by the housing.
  • the membrane and the vibrator, actuator or oscillator may be provided on the carrier or substrate.
  • the housing may have an opening, in particular, a central opening.
  • the housing may be configured so as to have a substantially annular shape, i.e., a ring shape with an opening in the centre.
  • a substantially annular shape i.e., a ring shape with an opening in the centre.
  • other shapes of the housing such as an oval shape with an opening in the centre, are also possible.
  • the membrane may be exposed to the outside through the opening of the housing.
  • a wiring for supplying power to the vibrator, actuator or oscillator, in particular, a piezo vibrator, a piezo actuator or a piezo oscillator, may be provided on the carrier or substrate .
  • the present invention also provides a nebuliser system having such a membrane nebuliser or vibrating membrane.
  • the membrane is preferably configured so as to have a
  • a nebuliser system which efficiently allows filling thereof with liquid during breathing assistance, such as a continuous positive airway pressure (CPAP) application, e.g., by filling the liquid into a liquid container, without a loss of pressure in the system.
  • the flow channel may have a dead volume, which may be defined by the volume between, e.g., a Y-piece bifurcation and the second connection or outlet channel to the patient.
  • the dead volume may be 30 ml or less, preferably 15 ml or less, more preferably 10 ml or less. In this way, the aerosol dosage efficiency and precision can be further enhanced, in
  • the nebulising device may be arranged in the flow channel such that an air flow, generated by the assisted breathing device and flowing through the flow channel from the first connection towards the second connection, i.e., a respiratory air flow, flows around the nebulising device.
  • nebulising device are surrounded by the respiratory air flow, e.g., in a sheath-like manner.
  • the deposition of liquid droplets in the nebulising device e.g., on inner walls thereof, is suppressed, while ensuring efficient mixing of the liquid droplets and the respiratory air with each other, thus enhancing aerosol generation.
  • a flow-around portion of the flow channel, through which the respiratory air flow can pass may be configured in the radial direction between the nebulising device, e.g., a vibratable membrane thereof, and the body in such a manner that a cross-sectional area of the flow-around portion is substantially equal to or larger than the smallest cross- sectional area of a line of the assisted breathing device that leads to the patient.
  • the smallest cross-sectional area of this line for adults is commonly of the order of
  • the smallest cross-sectional area of this line is commonly in the range of approximately 80 to 180 mm 2 .
  • the nebuliser or nebuliser system may further comprise a holding member.
  • the holding member may hold the nebulising device in position in the flow channel.
  • the holding member may comprise a plurality of through holes. The through holes may allow an air flow, generated by the assisted breathing device and flowing through the flow channel from the first connection towards the second connection, i.e., a respiratory air flow, to flow therethrough.
  • the through holes may be configured to allow the respiratory air to flow substantially unimpeded around the nebulising device .
  • the through holes may be configured to cause a respiratory air flow to be guided in a direction parallel to the aerosol plume emerging from the nebulising device by passing through the through holes, like a sheet air, which is favourable for an efficient transport of liquid droplets generated by the nebulising device. In particular, in this way, it can be ensured that the deposition of the aerosol on the inner surface via this transport is minimised.
  • the holding member may comprise a plurality of support elements, e.g., in the form of spokes or the like. Each support element may extend in a radial direction of the flow channel. The support elements may hold the nebulising device in position in the flow channel.
  • This configuration of the holding member allows for a
  • the through holes may be provided between and/or within the support elements.
  • the flow channel may comprise a tapered portion arranged downstream of the nebulising device, wherein, in the tapered portion, the diameter of the flow channel decreases in the direction from the first connection or the vibrating membrane towards the second connection.
  • the efficiency of aerosol transport towards the oral and/or nasal communication element such as the nasal prongs, a nose mask, a face mask or a mouthpiece, can be further improved.
  • the nebulising device may be configured such that the liquid is nebulised substantially parallel to the flow direction from the first connection to the second connection.
  • the nebulising device may be configured such that the liquid is nebulised in a direction which is substantially parallel to the flow direction from the first connection to the second connection.
  • the nebulising device is configured such that the liquid is nebulised substantially in the flow direction from the first connection to the second connection.
  • respiratory air can pass around the nebulising device in the inhalation cycle and the liquid to be nebulised is nebulised by the nebulising device parallel to, and preferably in, the direction of the respiratory air flow.
  • an aerosol flow is generated parallel to, and
  • the aerosol can be supplied to the patient with a particularly high degree of dosage efficiency and precision.
  • Such a configuration of the nebulising device may be
  • a nebulising device which comprises a vibratable membrane for nebulising the liquid and by arranging the vibratable membrane substantially
  • the nebulising device may be configured such that the liquid is nebulised within an angle of +/-45° to, and preferably in, the flow direction from the first connection to the second connection. In this way, a high degree of freedom for
  • arranging the nebulising device within the flow channel can be achieved, while reducing the occurrence of aerosol losses in the nebuliser.
  • the oral and/or nasal communication element may be a nasal communication element, such as the nasal prongs, configured for establishing fluid communication between the nebuliser and a patient's nose.
  • the nebuliser system may further comprise a liquid container for receiving the liquid to be nebulised by the nebulising device.
  • the liquid container may be in fluid communication with the body of the nebuliser.
  • the liquid container may be connected to the body.
  • the liquid container may be connected to the body in such a manner that it can be coupled and uncoupled.
  • the liquid container may form part of the nebuliser.
  • the liquid container may be integrally connected to the body of the nebuliser. In this way, in particular in combination with the provision of two connecting pieces and the second connection, which result in a tilt-stable unit, the flow of the liquid out of the liquid container can be further
  • the liquid container may be configured for directly
  • the liquid container may have a fluid communication interface and be configured for receiving, for example, a liquid- containing ampoule that comes into fluid communication with the liquid container via the fluid communication interface.
  • the fluid communication interface may be formed by or
  • an opening device such as a hollow spike or the like, and be configured to receive a liquid-containing ampoule to be opened by the opening device, e.g., similar to that disclosed, for example, in WO 2007/020073 for a known nebuliser/aerosol generator, to which reference is made for further details in this respect.
  • the nebuliser in particular, the body of the nebuliser, may comprise a nebulisation chamber into which the liquid is to be nebulised. If the nebulising device comprises a vibratable membrane, the membrane may be arranged between the liquid container and the nebulisation chamber.
  • the nebulisation chamber is arranged between the vibratable membrane and the second connection. In this way, the occurrence of aerosol losses in the nebuliser can be particularly efficiently suppressed.
  • the liquid container prefferably be configured to supply a constant dosage of liquid to the nebulising device, e.g., to a vibratable membrane thereof, up to a tilting angle of 45° in every direction from the vertical.
  • the unit consisting of the body of the nebuliser and the liquid container may be configured in a tilt-stable manner, e.g., by the two connecting pieces and the opposite second connection.
  • the liquid container may have a tapering in the direction of the membrane, which opens out into a liquid chamber that is closed by the membrane, with the tapering extending at least obliquely from a cylindrical portion of the liquid container to the liquid chamber.
  • a partial section of the tapering that is facing away from the membrane to extend with an angle range of between 10° and 40° to the vertical and, in the case of a perpendicularly arranged membrane, preferably also to the membrane, i.e., a lower portion of the liquid container that is closed in cross-section is configured, for example, in the shape of a cone and the central axis of the cone has an angle range of between 10° and 30° to the
  • the nebuliser system may further comprise a control for controlling the nebuliser, in particular, the nebulising device.
  • the control may be configured for controlling the nebuliser, in particular, the nebulising device, and for controlling the assisted breathing device. In this way, the efficiency of the system can be further enhanced.
  • control may be configured or set so that nebulisation of the liquid and thus aerosol generation is only triggered during an inhalation cycle, i.e., so that nebulisation by the nebulising device only occurs when the patient inhales.
  • the nebuliser system may further comprise an assisted
  • breathing device e.g., a positive pressure assisted
  • the nebuliser system may further comprise an adapter.
  • the adapter may be configured for adapting the nebuliser to the oral and/or nasal communication element, such as the nasal prongs, a nose mask, a face mask or a mouthpiece.
  • the nebuliser can be adapted or connected to the oral and/or nasal communication element, such as the nasal prongs, in a particularly efficient and reliable manner.
  • the oral and/or nasal communication element can be connected directly to the nebuliser, e.g., to the second connection thereof.
  • no intermediate elements, such as tubes, pipes or lines, are necessary for this connection. Hence, the occurrence of aerosol losses can be further suppressed.
  • the adapter may be integrally formed with the nebuliser, in particular, with the body of the nebuliser. In this case, a particularly reliable and steady fluid flow through the adapter to the oral and/or nasal communication element can be ensured .
  • the adapter may be attached, e.g., detachably or releasably attached, to the nebuliser, in particular, to the body of the nebuliser.
  • the adapter can be easily replaced.
  • the adapter may have an interface port arranged at the second connection for connecting the oral and/or nasal communication element, such as the nasal prongs, a nose mask, a face mask or a mouthpiece, to the nebuliser.
  • the interface port may be substantially rectangular, i.e., have a substantially
  • the interface port may be in the form of a recess or a cavity, e.g., a
  • nebuliser and oral and/or nasal communication element, such as nasal prongs, a nose mask, a face mask or a mouthpiece.
  • the adapter may have an adapter flow channel for allowing fluid flow from the second connection of the nebuliser to the oral and/or nasal communication element, such as the nasal prongs, a nose mask, a face mask or a mouthpiece.
  • At least a portion of the adapter flow channel may have an elongate, in particular, substantially oval or elliptic, cross-section in a plane perpendicular to the axial direction of the adapter flow channel, i.e., to the direction of fluid flow through the adapter flow channel.
  • the adapter flow channel may be arranged adjacent to and/or at least partly within the interface port.
  • the at least a portion of the adapter flow channel having an elongate cross-section may be arranged adjacent to and/or at least partly within the interface port.
  • the cross-section of the adapter flow channel may be constant or vary along the axial direction of the adapter flow
  • the area of the cross-section of the adapter flow channel may be constant or vary along the axial direction of the adapter flow channel.
  • the area of the cross-section of the adapter flow channel may decrease in the direction from the second connection of the nebuliser to the oral and/or nasal communication element. This decrease in cross-sectional area may be an at least partly continuous decrease or an abrupt, e.g., step-like, decrease.
  • the adapter flow channel By configuring the adapter flow channel so that the cross- sectional area thereof decreases in the direction from the second connection of the nebuliser to the oral and/or nasal communication element, the efficiency of aerosol transport towards the oral and/or nasal communication element, such as the nasal prongs, can be further improved.
  • the shape of the cross-section of the adapter flow channel may vary along the axial direction of the adapter flow channel.
  • the shape of the cross-section of the adapter flow channel may change from a substantially circular shape to an elongate, in particular, substantially oval or elliptic, shape in the direction from the second connection of the nebuliser to the oral and/or nasal communication element .
  • the adapter may be provided with a temperature sensor.
  • the temperature sensor may be configured to determine, detect, sense or measure the temperature of a fluid flowing through the adapter.
  • the temperature sensor may be configured to determine, detect, sense or measure the temperature of a fluid flowing through the adapter flow channel.
  • the temperature sensor may be at least partly arranged within the adapter flow channel.
  • the temperature sensor may extend into the adapter flow channel.
  • the temperature sensor may extend into the adapter flow channel through an opening provided in a wall, e.g., an outer wall, of the adapter .
  • the temperature sensor allows for the temperature of a fluid flowing through the adapter, in particular, through the adapter flow channel, to be reliably monitored. Thus, it can be ensured that the fluid supplied to a patient has the desired temperature.
  • the temperature of the fluid flowing through the adapter can be monitored by means of the temperature sensor and be controlled so as to be in the range of 35°C to 46°C, preferably 36°C to 45°C, more preferably 36°C to 43°C, even more preferably 36°C to 42°C, yet even more preferably 37°C to 39°C and still even more preferably around 37°C.
  • the assisted breathing device and/or the nebuliser may be
  • the nebuliser may be configured so that the nebulising device is switched off if the temperature determined by the temperature sensor exceeds a threshold value. In the switched off state of the nebulising device, no liquid is being nebulised.
  • the threshold value may be, for example, 46°C, 45°C, 44°C, 43°C, 42°C, 41°C, 40°C, 39°C or 38 °C .
  • the temperature sensor allows for the temperature of the fluid flowing through the adapter to be reliably monitored. Hence, the temperature of the fluid exiting the nebuliser system, in particular, through the oral and/or nasal
  • the difference between the temperature of the fluid at the position of the temperature sensor and the temperature of the fluid at the position where the fluid exits the nebuliser system, in particular, through the oral and/or nasal communication element, can be established or
  • the temperature of the fluid exiting the nebuliser system can be accurately determined on the basis of the temperature detected by the temperature sensor.
  • this temperature difference may be in the range of 1°C to 5°C, 2°C to 4°C or 2°C to 3°C.
  • the threshold value of the temperature determined by the temperature sensor may be chosen so that the temperature of the fluid exiting the nebuliser system does not exceed a desired limit, such as 43 °C, 42 °C, 41 °C, 40°C, 39°C or 38°C.
  • the nebuliser may be configured so that the nebulising device is switched off if no more liquid to be nebulised is present in the nebulising device. In this way, an undesired increase of the temperature of the fluid flowing through the adapter can be minimised or even eliminated.
  • Such a configuration of the nebuliser may be used in combination with the temperature sensor, allowing for the temperature of the fluid flowing through the adapter to be kept within a desired range in a particularly reliable and efficient manner.
  • the temperature sensor may be arranged in a housing.
  • the housing may be, e.g., made of a metal or a polymer material.
  • the housing may be made of stainless steel, a plastic material and/or a flexible material.
  • a material of the housing for example, polypropylenes (PP) , also known as polypropenes (a thermoplastic polymer) , polyurethane
  • thermoplastic elastomers PTE
  • silicones and/or the like may be used.
  • the temperature sensor may comprise or consist of a Negative Temperature Coefficient (NTC) sensor, in particular, a
  • Negative Temperature Coefficient thermistor.
  • NTC Negative Temperature Coefficient
  • the temperature sensor may comprise or consist of a Positive Temperature Coefficient (PTC) sensor, in particular, a Positive Temperature
  • PTC Coefficient
  • the temperature sensor comprises or consists of a Negative Temperature Coefficient (NTC) sensor, in particular, a Negative Temperature Coefficient (NTC) thermistor .
  • NTC Negative Temperature Coefficient
  • NTC Negative Temperature Coefficient
  • the liquid to be nebulised by the nebulising device may be a pharmaceutical formulation, e.g., in form of an aqueous solution or an aqueous suspension.
  • the liquid may be a pharmaceutical formulation comprising an active compound, enabling generation of a pharmaceutical aerosol by the nebulising device for the delivery of the active compound to the patient.
  • An active compound is a natural, biotechnology-derived or synthetic compound or mixture of compounds useful for the diagnosis, prevention, management or treatment of a disease, condition or symptom of a human, in particular, a neonate, or an animal.
  • Other terms which may be used as synonyms of active compounds include, for example, active ingredient, active pharmaceutical
  • the fluid could be of a liquid, solution, suspension, colloidal mixture or liposomal
  • formulation form and can be prepared, mixed or opened before or during the application.
  • the active compound comprised in the fluid to be nebulised or aerosolised by the nebuliser or a so-called aerosol generator may be a drug substance or a medicament which is useful for the prevention, management, diagnosis or treatment of any disease, symptom or condition affecting the body cavities, the abdomen, the eyes, the intestine, the stomach, the nose, the nasal cavities, the sinuses, the osteomeatal complex, the mouth, the trachea, the lungs, the bronchi, the bronchioles, the alveoli and/or the respiratory tract.
  • an aerosol comprising an active compound which is useful for the prevention, management, diagnosis or treatment of any disease, symptom or condition affecting pulmonary development
  • surfactant compounds which may be derived from: surface active agent (surfactant) , which may be synthetic surfactant , recombinant surfactant proteins, pulmonary surfactant, exogenous pulmonary surfactant, natural pulmonary surfactants, modified natural pulmonary
  • active compounds which may be useful for serving one of the purposes named previously and that may be used together with the present invention are, for example, substances selected from the group consisting of anti
  • phosphodiesterase inhibitors beta-2-sympathicomimetics, decongestants, vasoconstrictors, anticholinergics,
  • immunoglobulins immunomodulators , mucolytics, anti-allergic drugs, antihistaminics , mast-cell stabilising agents, tumor growth inhibitory agents, wound healing agents, local
  • anaesthetics antioxidants, oligonucleotides, peptides, proteins, vaccines, vitamins, plant extracts, cholinesterase inhibitors, vasoactive intestinal peptide, serotonin receptor antagonists, and heparins, glucocorticoids, anti-allergic drugs, antioxidants, vitamins, leucotriene antagonists, anti- infective agents, antibiotics, antifungals, antivirals, mucolytics, decongestants, antiseptics, cytostatics,
  • immunomodulators vaccines, wound healing agents, local anaesthetics, oligonucleotides, xanthin derived agents, peptides, proteins and plant extracts.
  • Such compound may be used in the form of a suspension, a solution, a colloidal formulation (i.e., liposomal), etc.
  • anti-inflammatory compounds examples include glucocorticoids and non-steroidal anti-inflammatory agents such as betamethasone, beclomethasone, budesonide, ciclesonide, dexamethasone, desoxymethasone, fluoconolone acetonide, fluocinonide, flunisolide, fluticasone,
  • non-steroidal anti-inflammatory agents such as betamethasone, beclomethasone, budesonide, ciclesonide, dexamethasone, desoxymethasone, fluoconolone acetonide, fluocinonide, flunisolide, fluticasone,
  • NSAIDs non-steroidal anti-inflammatory drugs
  • ASA ibuprofen and acetylsalicylic acid
  • anti-infective agents whose class or therapeutic category is herein understood as comprising compounds which are effective against bacterial, fungal, and viral
  • infections i.e. encompassing the classes of antimicrobials, antibiotics, antifungals, antiseptics, and antivirals, are penicillins, including benzylpenicillins (penicillin-G- sodium, clemizone penicillin, benzathine penicillin G) , phenoxypenicillins (penicillin V, propicillin) ,
  • aminobenzylpenicillins (ampicillin, amoxycillin,
  • bacampicillin acylaminopenicillins (azlocillin,
  • penicillins oxacillin, cloxacillin, dicloxacillin,
  • cephalosporins including cefazolins (cefazolin,
  • cefazedone cefuroximes (cefuroxim, cefamandole, cefotiam) , cefoxitins (cefoxitin, cefotetan, latamoxef, flomoxef) , cefotaximes (cefotaxime, ceftriaxone, ceftizoxime,
  • cefmenoxime cefmenoxime
  • ceftazidimes ceftazidime, cefpirome
  • cefepime cefalexins (cefalexin, cefaclor, cefadroxil, cefradine, loracarbef, cefprozil) , and cefiximes (cefixime, cefpodoxim proxetile, cefuroxime axetil, cefetamet pivoxil, cefotiam hexetil) , loracarbef, cefepim, clavulanic acid / amoxicillin, Ceftobiprole ; synergists, including beta-lactamase inhibitors, such as clavulanic acid, sulbactam, and tazobactam; carbapenems, including imipenem, cilastin, meropenem, doripenem, tebipenem, ertapenem, ritipenam, and biapenem; monobactams, including aztreonam; aminoglycosides, such as
  • amikacin isepamicin, arbekacin, tobramycin, netilmicin, spectinomycin, streptomycin, capreomycin, neomycin,
  • paromoycin paromoycin, and kanamycin
  • macrolides including erythromycin, clarythromycin, roxithromycin, azithromycin, dithromycin, josamycin,
  • spiramycin and telithromycin include gyrase inhibitors or fluroquinolones , including
  • tetracyclins including tetracyclin, oxytetracyclin, rolitetracyclin, minocyclin, doxycycline, tigecycline and aminocycline ; glycopeptides , inlcuding vancomycin, teicoplanin, ristocetin, avoparcin, oritavancin, ramoplanin, and peptide
  • polypeptides including plectasin, dalbavancin,
  • micafungin including nitrofurantoin and
  • nitrofuranzone polyenes, including amphotericin B, natamycin, nystatin, flucytosine ; other antibiotics, including tithromycin, lincomycin, clindamycin, oxazolindiones ( linzezolids ) , ranbezolid, streptogramine A+B, pristinamycin A+B, Virginiamycin A+B, dalfopristin /quinupristin (Synercid) , chloramphenicol, ethambutol, pyrazinamid, terizidon, dapson, prothionamid, fosfomycin, fucidinic acid, rifampicin, isoniazid,
  • antivirals including aciclovir, ganciclovir, birivudin, valaciclovir, zidovudine, didanosin, thiacytidin, stavudin, lamivudin, zalcitabin, ribavirin, nevirapirin, delaviridin, trifluridin, ritonavir, saquinavir, indinavir, foscarnet, amantadin, podophyllotoxin, vidarabine, tromantadine, and proteinase inhibitors, siRNA based drugs; antiseptics, including acridine derivatives, iodine- povidone, benzoates, rivanol, chlorhexidine;
  • antibody also known as an immunoglobulin (Ig), including immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM); as well as fragments of antibodies, also known as Fab (fragment, antigen-binding) region, complementarity determining regions (CDRs) , Fc (Fragment, crystallizable) region, or Fc receptors; cytostatics and metastasis inhibitors; alkylants, such as nimustine, melphanlane, carmustine, lomustine, cyclophosphosphamide, ifosfamide, trofosfamide, chlorambucil, busulfane, treosulfane, prednimustine, thiotepa; antimetabolites, e.g. cytarabine, fluorouracil ,
  • methotrexate methotrexate, mercaptopurine, tioguanine
  • alkaloids such as vinblastine, vincristine, vindesine
  • antibiotics such as alcarubicine, bleomycine
  • transition group elements e.g. Ti, Zr, V, Nb, Ta, Mo, W, Pt
  • carboplatinum, cis-platinum and metallocene compounds such as titanocendichloride ; amsacrine, dacarbazine, estramustine, etoposide, beraprost, hydroxycarbamide, mitoxanthrone, procarbazine, temiposide ; paclitaxel, gefitinib, vandetanib, erlotinib, poly-ADP- ribose-polymerase (PRAP) enzyme inhibitors, banoxantrone, gemcitabine, pemetrexed, bevacizumab, ranibizumab.
  • transition group elements e.g. Ti, Zr, V, Nb, Ta, Mo, W, Pt
  • metallocene compounds such as titanocendichloride ; amsacrine, dacarbazine, estramustine
  • Examples of potentially useful mucolytics are DNase, P2Y2- agonists (denufosol) , drugs affecting chloride and sodium permeation, such as N- (3, 5-Diamino-6-chloropyrazine-2- carbony) -N' - ⁇ 4- [4- (2, 3-dihydroxypropoxy) - phenyl ] butyl ⁇ guanidine methanesulfonate (PARION 552-02), heparinoids, guaifenesin, acetylcysteine, carbocysteine, ambroxol, bromhexine, tyloxapol, lecithins, myrtol,
  • DNase DNase
  • P2Y2- agonists denufosol
  • drugs affecting chloride and sodium permeation such as N- (3, 5-Diamino-6-chloropyrazine-2- carbony) -N' - ⁇ 4- [4- (2, 3-dihydroxypropoxy
  • surfactant synthetic surfactant and recombinant surfactant proteins .
  • decongestants which may be useful to reduce the swelling of the mucosa are phenylephrine, naphazoline, tramazoline, tetryzoline, oxymetazoline, fenoxazoline, xylometazoline, epinephrine, isoprenaline, hexoprenaline, and ephedrine.
  • decongestants which may be useful to reduce the swelling of the mucosa are phenylephrine, naphazoline, tramazoline, tetryzoline, oxymetazoline, fenoxazoline, xylometazoline, epinephrine, isoprenaline, hexoprenaline, and ephedrine.
  • Examples of potentially useful local anaesthetic agents include benzocaine, tetracaine, procaine, lidocaine and bupivacaine .
  • antiallergic agents examples include the afore-mentioned glucocorticoids, cromolyn sodium, nedocromil, cetrizin, loratidin, montelukast, roflumilast, ziluton, omalizumab, heparinoids and other antihistamins , including azelastine, cetirizin, desloratadin, ebastin, fexofenadin, levocetirizin, loratadin.
  • anticholinergic agents examples include ipratropium bromide, tiotropium bromide, oxitropium bromide, glycopyrrolate .
  • beta-2-sympathicomimetic agents examples include salbutamol, fenoterol, formoterol,
  • indacaterol isoproterenol, metaproterenol , salmeterol, terbutaline, clenbuterol, isoetarine, pirbuterol, procaterol, ritodrine .
  • xanthine derived agents examples include theophylline, theobromine, caffeine.
  • Antisense oligonucleotides are short synthetic strands of DNA (or analogs) that are complimentary or antisense to a target sequence (DNA, RNA) designed to halt a biological event, such as transcription, translation or splicing. The resulting inhibition of gene expression makes oligonucleotides
  • syncytical virus by, AVE-7279 to treat asthma and allergies, TPI-ASM8 to treat allergic asthma, 1018-ISS to treat cancer.
  • examples of potentially useful peptides and proteins include antibodies against toxins produced by microorganisms,
  • antimicrobial peptides such as cecropins, defensins,
  • the pharmaceutical formulation may comprise a pulmonary surfactant (derived from: surface active agent) .
  • the pulmonary surfactant may be an exogenous pulmonary surfactant .
  • the pulmonary surfactant may belong to the class of "modified natural" pulmonary surfactants which are lipid extracts of minced mammalian lung or lung lavage. These preparations have variable amounts of SP-B and SP-C proteins and, depending on the method of extraction, may contain non-pulmonary
  • surfactant lipids proteins or other components.
  • modified natural pulmonary surfactants present on the market, like SurvantaTM, are spiked with synthetic components such as tripalmitin, dipalmitoylphosphatidylcholine and palmitic acid .
  • Current modified natural pulmonary surfactants include, but are not limited to, bovine lipid pulmonary surfactant
  • bovactant AlveofactTM, Thomae, Germany
  • bovine pulmonary surfactant Pulmonary surfactant TATM, Tokyo Tanabe, Japan
  • beractant SturvantaTM, Abbott Laboratories, Inc., Abbott Park, Ill .
  • the pulmonary surfactant may belong to the class of
  • artificial pulmonary surfactants which are simply mixtures of synthetic compounds, primarily phospholipids and other lipids that are formulated to mimic the lipid composition and behaviour of natural pulmonary surfactant. They are devoid of pulmonary surfactant proteins. Examples of artificial
  • surfactants include, but are not limited to, pumactant
  • the pulmonary surfactant may belong to the class of
  • reconstituted pulmonary surfactants which are artificial pulmonary surfactants to which have been added pulmonary surfactant proteins/peptides isolated from animals or proteins/peptides manufactured through recombinant technology such as those described in WO 95/32992, or synthetic
  • surfactants examples include, but are not limited to, poractant alfa (CurosurfTM Chiesi Farmaceutici S.p.A.) and lucinactant (SurfaxinTM, Windtree Therapeutics, Inc., Warrington, Pa.) and the product having the composition disclosed in WO 2010/139442.
  • the dose of the pulmonary surfactant may be comprised between 150 and 600 mg/kg body weight.
  • the dose of the pulmonary surfactant may be comprised between 200 and 600 mg/kg, preferably between 300 and 500 mg/kg, more preferably between 150 and 300 mg/kg, and even more
  • the pharmaceutical formulation may be a natural, modified and/or synthetic pharmaceutical formulation.
  • the nebuliser system of the present invention may further comprise the liquid to be nebulised, e.g., the pharmaceutical formulation .
  • the patient to be treated by using the nebuliser system of the present invention may be a spontaneously breathing pre term neonate having a gestational age of 26 to 32 weeks suffering of RDS .
  • the nebuliser system of the invention can be particularly advantageously used for the treatment of neonates.
  • the assisted breathing device such as the continuous breathing
  • positive airway pressure (CPAP) device may be a positive pressure assisted breathing device, such as a PAP (Positive Airway Pressure) , a BiPAP (Bilevel Positive Airway Pressure) , a CPAP (Continuous Positive Airway Pressure) , a nCPAP (nasal CPAP) , a NIPPV (Non Invasive Positive Pressure Ventilation) , an artificial respiration machine, a respirator, a lung ventilator, an Invasive Ventilator (IV), a Non-Invasive
  • Ventilator NAV
  • mechanical ventilator or a mechanical ventilator
  • a positive pressure assisted mode may be applicable in different assisted breathing devices, such as the devices mentioned above.
  • the nebuliser system of the present invention may further comprise the oral and/or nasal communication element, such as the nasal prongs, a nose mask, a face mask, a mouthpiece or an endotracheal tube, as well as a tracheostomy tube as a further communication element.
  • the oral and/or nasal communication element such as the nasal prongs, a nose mask, a face mask, a mouthpiece or an endotracheal tube, as well as a tracheostomy tube as a further communication element.
  • the oral and/or nasal communication element may comprise an interface member for connection to the interface port of the adapter.
  • the interface member may be configured for being at least partly received within the interface port.
  • interface member may have a substantially rectangular shape, i.e., a substantially rectangular shape in a view along the direction of fluid flow through the interface member.
  • the interface member may have one or more, e.g., two,
  • the oral and/or nasal communication element may comprise one or more, e.g., two, fluid guiding members for guiding a fluid, such as an aerosol, to the patient's nose and/or mouth. If the oral and/or nasal communication element
  • the one or more fluid guiding members are in fluid communication with the interface member. If the oral and/or nasal communication element comprises more than one, e.g., two, fluid guiding members, the fluid guiding members may be in fluid communication with the interface member through a single, i.e., common, channel or through a plurality of, for example, two, separate channels. In
  • each fluid guiding member may be in fluid
  • each fluid guiding member may be in fluid
  • the oral and/or nasal communication element may comprise two fluid guiding members and the interface member may have two communication openings, for establishing fluid communication between the nebuliser and respective nasal entrances of the patient.
  • the oral and/or nasal communication element may have a support member, such as a strap or the like, for holding the oral and/or nasal communication element in position on the patient's head.
  • the adapter may have a support member, such as a strap or the like, for holding the oral and/or nasal communication element in position on the patient's head.
  • the oral and/or nasal communication element may be a nasal communication element, such as the nasal prongs, a nose mask, a face mask or a mouthpiece.
  • the nasal communication element may have two openings, each opening being configured for establishing fluid communication between the nebuliser and a respective nasal entrance of the patient.
  • the nasal communication element may have a support member, such as a strap or the like, for holding the nasal
  • the adapter may comprise the support member, such as a strap or the like, or the adapter may be configured to be attached to the support member.
  • the adapter may comprise a plurality of support members, such as a plurality of straps, bands, belts, tapes or the like, or the adapter may be configured to be attached to a plurality of support members.
  • the support member may be in the form of a loop or a lug.
  • the support member may be configured to form a loop or a lug.
  • the support member may be a strap or the like which is in the form of a loop or a lug or which is configured to form a loop or a lug.
  • the support member such as a strap or the like, may be configured to be attached, e.g., at one of its ends, to the patient, for example, to a cap or hood worn by the patient.
  • the support member may be configured to be attached to the patient at one of its ends and to the adapter at another one of its ends.
  • the support member may be provided with a Velcro fastener, an adhesive, e.g., a pressure sensitive adhesive, or a snap fastener, such as a push button, for attachment to the patient.
  • the support member such as a strap or the like, may be provided, at one end, with a slit through which another end of the support member can be inserted, thereby forming a loop or a lug.
  • the adapter may have one or more, preferably two, openings through which one or more, preferably two, support members can be respectively inserted.
  • two such openings may be arranged on opposite sides of the interface port.
  • Two such openings may be arranged on opposite sides and/or at opposite ends of the adapter.
  • Each of the one or more, preferably two, openings may be surrounded by a wall or walls of the adapter.
  • the wall or walls of the adapter may be provided with a through-hole, such as a slit or a slot.
  • the through-hole, such as a slit or a slot may be provided in an outer wall or outer walls of the adapter.
  • the through-hole such as a slit or a slot, may be configured to allow insertion of the support member into the respective opening via the through-hole.
  • the provision of such a through-hole allows for the adapter to be attached to an existing support member, e.g., a support member already attached to the patient, in a particularly simple and
  • the invention further provides a holding system for holding a nebuliser or a nebuliser system.
  • the holding system comprises a base, a holding arm extending from the base, and a holding element configured to hold the nebuliser or the nebuliser system.
  • the holding arm has a first end and a second end opposite to the first end. The first end of the holding arm is attached to the base.
  • the holding element is attached to the holding arm substantially at the second end of the holding arm.
  • the holding element may be attached to the holding arm at the second end of the holding arm.
  • the holding system of the invention may be configured for holding the nebuliser system of the invention and/or for holding the nebuliser of the nebuliser system of the
  • the holding system allows for the nebuliser or nebuliser system to be stably held in its position, so that efficient aerosol transport from the nebuliser to a patient, in
  • the base enables secure and stable placement of the holding system, e.g., on a placement surface, such as a hospital bed or the like, or on the patient's body. Since the holding element is arranged in separation from the base, i.e., separated or spaced from the base through the holding arm, accessibility of the patient, e.g., for further treatment or tests, is not considerably impaired. This is particularly beneficial for the treatment of children, especially
  • components of the nebuliser system such as tubes, pipes, leads etc., may be held by and/or guided over the holding element, so that the patient remains readily accessible.
  • the first end of the holding arm may be detachably or
  • the holding arm can be replaced in a simple manner.
  • a longer holding arm may be employed for treatment of an adult, while a shorter holding arm may be used for treatment of a child, in particular, a neonate.
  • the holding system can be easily adapted to the requirements of the patient to be treated .
  • the holding element may be detachably or releasably attached to the holding arm substantially at the second end of the holding arm.
  • the holding element can be
  • the holding system can be easily adapted to different types of nebulisers and/or nebuliser systems.
  • the holding system can hold the nebuliser system safely in position. Further the holding system may lift weight off the nose of the patient, such as a baby or a neonate, and may render additional rest-weight compatible with the assisted breathing device's tubing, as it may be acceptable.
  • the holding system and/or a possible adapter for communication elements such as nasal prongs, a nose mask, a face mask or a mouthpiece, may be configured to allow slight movement of the patient's head.
  • the nebuliser system position may be adjustable in the x-axis, the y-axis, and/or the z- axis while the nebuliser system is rotatable in the aerosol generating axis or spray axis.
  • the nebuliser system position advantageously guarantees an easy fluid or liquid (re-) filling for example of the optional reservoir.
  • This may include complete reservoir drainage and ergonomic connection of communication elements, such as nasal prongs, a nose mask, a face mask or a mouthpiece.
  • the holding system may be used in an incubator (e.g., disposed on a mattress) .
  • the holding system may be configured so as not to obscure vision of or access to the patient
  • a baby or a neonate for the operator's procedures, such as a physician's procedures, a doctor's procedures, and nursing procedures in the health care system.
  • the holding system can be easily set up and used, for example, by nurses and
  • the holding system can be used in the successive treatment of a plurality of patients, i.e., is re-usable.
  • the base has a curved shape.
  • the base has substantially a U-shape.
  • a curved shape of the base enables particularly secure and stable placement of the holding system, e.g., on a placement surface.
  • the curved shape allows for the base to be arranged at least partly around the head of a patient, such as a child, in particular, a neonate.
  • a particularly high degree of accessibility of the patient can be achieved.
  • the position of the patient's head relative to the base can be fixed in a simple manner, e.g., by using a towel or the like.
  • the towel or the like can be placed on the base, e.g., between the patient's head and the base, or be at least partially wrapped around the base. Fixing the position of the patient's head in this manner is particularly beneficial in the treatment of children, especially neonates.
  • the holding arm may be flexible.
  • the holding arm may be configured so that it can be, e.g., substantially freely, bent, inflected or deformed into a desired shape and subsequently maintains this shape, i.e., remains in this shape .
  • the holding system By configuring the holding arm in a flexible manner, the holding system can be easily and efficiently adapted to the specific requirements of the patient to be treated. Thus, an optimal arrangement of the nebuliser or the nebuliser system relative to the patient can be achieved.
  • the holding arm may have a length in the range of 10 cm to 60 cm, preferably 20 cm to 50 cm and more preferably 30 cm to 40 cm. In this way, good accessibility of the patient and, at the same time, a robust arrangement of the holding system can be particularly reliably ensured.
  • the holding element may have a strap or a string, such as a silicone string, for holding the nebuliser or the nebuliser system. In this way, a particularly simple configuration of the holding system can be achieved.
  • the holding element may have a plurality of holding portions, e.g., two or more holding portions, three or more holding portions, four or more holding portions, or five or more holding portions.
  • Each holding portion may be configured for holding a component of the nebuliser system, such as a part of the body of the nebuliser, the entire body of the
  • the holding portions may be in the form of recesses, cut-outs or cavities.
  • the recesses, cut outs or cavities may be configured for at least partly receiving therein the components of the nebuliser system.
  • the invention further provides a combination comprising the nebuliser system of the invention and the holding system of the invention.
  • the invention provides a method of administering an aerosol to a patient, in particular, a child, especially a neonate, using the nebuliser system of the invention or the combination of the invention.
  • the method comprises generating an aerosol by nebulising the liquid by means of the
  • nebulising device and supplying the aerosol to the patient through the second connection.
  • the method of the invention is a method of using the
  • nebuliser system of the invention and the combination of the invention .
  • Fig. 1 shows a perspective view of a nebuliser system according to an embodiment of the present
  • FIG. 2 shows a top view of the nebuliser of Fig. 1
  • Fig . 3 shows an upside down side view of the nebuliser of Fig. 1;
  • Fig. 4 shows a longitudinal cross-section through the nebuliser of Fig. 1 along the line A-A in Fig. 2;
  • Fig . 5 shows a longitudinal cross-section through the nebuliser of Fig. 1 along the line B-B in Fig. 3;
  • Fig . 6 shows a perspective view of a nebuliser system according to another embodiment of the present invention, which is schematically coupled to an assisted breathing device;
  • Fig. 7 shows a perspective view of a nebuliser system according to yet another embodiment of the present invention, which is schematically coupled to an assisted breathing device;
  • Fig. 8 shows a cross-sectional view of a nebuliser
  • Fig. 9 shows a perspective view of the nebuliser system according to the embodiment of the present invention shown in Fig. 1, comprising the
  • nebuliser an adapter and a nasal communication element ;
  • Fig. 10 shows the adapter and the nasal communication
  • FIG. 10 (b) is a perspective view showing the adapter and the nasal communication element in the connected state;
  • Fig. 11 shows a perspective top view of the adapter of Fig. 9;
  • Fig. 12 shows a perspective bottom view of the adapter of
  • Fig. 13 shows an enlarged perspective view of the nasal communication element shown in Figs. 9 and 10;
  • Fig. 14 shows a perspective view of a nasal communication element of another type
  • Fig. 15 shows perspective views of further nasal
  • Fig. 16 shows a partially exploded perspective view of a holding system according to an embodiment of the present invention
  • Fig. 17 shows a perspective view of a combination
  • Fig. 18 shows a diagram presenting experimental data of a first example of experimental studies performed using the nebuliser system of the present
  • Fig. 19 shows a diagram presenting further experimental data of the first example of experimental studies performed using the nebuliser system of the present invention.
  • Fig. 20 shows a diagram presenting experimental data of a second example of experimental studies performed using the nebuliser system of the present
  • Fig. 21 shows a diagram presenting further experimental data of the second example of experimental studies performed using the nebuliser system of the present invention.
  • Fig. 22 shows a perspective bottom view of an adapter
  • Fig. 23 shows a perspective bottom view of an adapter
  • Fig. 24 shows a perspective view of an adapter according to another embodiment of the present invention.
  • the preferred embodiments relate to a nebuliser system, a holding system, a combination comprising the nebuliser system and the holding system, and a method of administering an aerosol to a neonate using the combination.
  • a nebuliser of a nebuliser system according to an embodiment of the present invention will be described with reference to Figs. 1 to 5.
  • the nebuliser system shown in Fig. 1 comprises the nebuliser, an adapter 104, such as the adapter 300 shown in Figs. 11 and 12, and an oral and/or nasal communication element in the form of nasal prongs 200, a nose mask 600 or a face mask 700.
  • the nasal prongs 200, the nose mask 600 or the face mask 700 can be connected to the nebuliser via the adapter 104, as is indicated by the dashed line 103 in Fig. 1.
  • the nebuliser shown in Figs. 1 to 5 comprises three main components, namely a first body part 1, a second body part 2 and a nebulising device 3 (see Fig. 2) .
  • the first and second body parts 1 and 2, which together form the body, are
  • the first body part 1 comprises a first connection 10, which is composed of two connecting pieces 11, 12.
  • the first connecting piece 11 is configured so as to connect with an air supply line 101 of an assisted breathing device 100.
  • the assisted breathing device 100 is a currently preferred embodiment of an assisted breathing device.
  • the second connecting piece 12 is in turn configured to be connected to an air exhaust line 102 of the assisted breathing device 100.
  • the air supply line 101 and the air exhaust line 102 are thereby each formed by a separate tube (not shown) , which may have, for example, an inner diameter of 22 mm for adults or an inner diameter of 10 mm and 15 mm for children.
  • the connecting pieces 11, 12 are each configured such that it is possible to couple these conventional tubes to the
  • each of the connecting pieces 11, 12 has a bent portion at which the respective connecting piece 11, 12 is bent upward by approximately 90°. These bent portions allow for the connecting pieces 11, 12 to be coupled to the tubes of the air supply line 101 and the air exhaust line 102 in a
  • aerosol therapy can be performed with a particularly high degree of efficiency and precision .
  • a bypass 13 is furthermore formed in the first body part 1 (see Figs. 4 and 5), said bypass 13 being arranged before (i.e., upstream in the direction of flow of the respiratory air) the nebulising device 3.
  • This bypass 13 ensures that a basic flow generated by the assisted breathing device 100 to regulate the respiratory air to a patient 800 (see Fig. 17) can flow, outside of an inhalation cycle and/or an exhalation cycle of the patient 800, directly from the air supply line 101 into the air exhaust line 102 via the connecting piece 11, the bypass 13 and the connecting piece 12, without passing the nebulising device 3 (as is indicated by a dashed arrow in Fig. 5) .
  • This basic flow has a flow rate of up to 30 1/min.
  • the basic flow is often also referred to as a "bias flow" .
  • the assisted breathing device 100 may be a positive pressure assisted breathing device, such as a PAP, a BiPAP, a CPAP, a nCPAP, a NIPPV, a IV, a NIV, a respirator, a ventilator, or a similar device that uses equivalent modes.
  • a positive pressure assisted breathing device such as a PAP, a BiPAP, a CPAP, a nCPAP, a NIPPV, a IV, a NIV, a respirator, a ventilator, or a similar device that uses equivalent modes.
  • a compressor or a pressurized gas source could be used: the pressure is modulated by a pressure regulator with a mechanical filter to avoid dust flowing through the system.
  • the pressure is
  • Non-invasive ventilation supports require the delivery of humidified and heated air in order to avoid drying of the airway mucosa.
  • humidified air is utilized at a temperature between 35°C and 42°C, more preferably between 37°C and 39°C and even more preferably around 37°C.
  • the humidified air is utilized at body
  • the humidity is between 95% and 100% (non-condensing) , more preferably between 99% and 100%.
  • humidified and heated air may be used ambient air and/or air mixture and may include additional oxygen, up to 100% oxygen and/or air concentrators and/or oxygen supply.
  • the skilled person in the art shall suitably adjust the temperature and the relative humidity as well as the oxygen content of the air.
  • the patient 800 may be a spontaneously breathing pre-term neonate having a gestational age of 26 to 32 weeks suffering of RDS (see Fig. 17) .
  • the first body part 1 furthermore also comprises a liquid container 14 for receiving a liquid to be nebulised.
  • a liquid container 14 for receiving a liquid to be nebulised. Examples of possible liquids to be received in the liquid container 14 are given above.
  • the liquid may be a
  • the pharmaceutical formulation in form of an aqueous solution or an aqueous suspension.
  • the pharmaceutical formulation may comprise a pulmonary surfactant.
  • the dose of the pulmonary surfactant may be comprised between 150 and 600 mg/kg body weight .
  • the liquid container 14 is preferably an integral component of the first body part 1. However, it may also be configured such that it can be partially or completely coupled and uncoupled . It is also conceivable that the liquid container 14 does not directly accommodate the liquid to be nebulised but rather that a device, for example a spike, is provided in the liquid container 14 so as to open, for example pierce, an ampoule that can be inserted into the liquid container 14, out of which the liquid to be nebulised can be supplied to the nebulising device 3 and a liquid chamber 24 to be described later. Such a configuration is shown in Fig. 8.
  • the liquid container 14 may be provided with an opening element 128, such as a spike or the like, which is configured to pierce an ampoule 129 that contains the fluid.
  • an opening element 128 such as a spike or the like, which is configured to pierce an ampoule 129 that contains the fluid.
  • the opening element 128 pierces a bottom 130 of the ampoule 129 and folds it back so that fluid can flow into the fluid chamber 24.
  • the opening element 128 is configured so as to be hollow for allowing fluid to pass therethrough.
  • the liquid container 14 has a substantially cylindrical portion 15 that has a
  • An external screw thread 16 is formed on the outer circumferential surface of the cylindrical portion 15 at the end of the cylindrical portion 15 which is facing away from the nebulising device 3.
  • An internal screw thread 17 of a lid 18, which is formed on the inner circumferential surface of the lid 18, can be engaged with this external screw thread 16 so that the lid 18 can be screwed onto the cylindrical portion 15 of the liquid container 14.
  • the lid 18 further comprises a circumferential collar 19 on its inner surface which, when the lid 18 is screwed on, sealingly engages, either directly or indirectly via a sealing material, with the inner surface of the
  • cylindrical portion 15 comprises a surrounding groove 20, in which one end of a lid securing means 21 (see Fig. 1) can be fixed, the other end of which can be attached to a mushroom-shaped projection 22 of the lid 18.
  • a tapering portion 23 is located at the end of the
  • the tapered portion 23 is composed in cross-section of a wall 26 extending
  • the first body part 1 further comprises a surrounding collar 27 at its opposite end to the first connection 10, which collar 27 can be coupled to the second body part 2 (see below) .
  • a sealing material 28 is injection moulded radially inside this collar 27 or is produced in a two-component process together with the first body part 1 that is made of a hard resilient plastic.
  • This sealing material 28 comprises a circumferential projection 29.
  • a surrounding sealing lip 30 that abuts the liquid chamber 24 and is pressed against the vibratable membrane 37 for sealing such that the liquid chamber 24 is tightly sealed by the membrane 37 and the sealing lip 30.
  • the second body part 2 comprises the second connection 31, which is formed by a connecting piece 32.
  • This connecting piece 32 is preferably designed in a similar manner to the tube to be respectively connected to the connecting pieces 11 and 12, which forms lines 101 and 102. In this way, it can be ensured that the shown nebuliser can only be integrated into the assisted breathing device 100 in the proper manner. Other designs for achieving this are also conceivable. It is only important that the connections 31 and 10 are not designed in an identical manner in order to rule out the possibility that one of lines 101, 102, each formed by tubes, is connected to the connecting piece 32 or that the adapter 104 is connected to one of the connecting pieces 11 or 12.
  • the second body part 2 further comprises a plurality of locking means distributed over its circumference, in this case locking catches 33.
  • locking catches 33 In the shown embodiment, six such locking catches 33 or snap-in hooks are provided. However, fewer or more such devices are also conceivable.
  • the locking catches 33 are thereby designed in such a manner that in the assembled state, they can be engaged with the surrounding collar 27 of the first body part 1 in that they grip behind the collar 27 so that the first and second body parts 1 and 2 can be connected with one another.
  • Radially inside the locking catches 33 the second body part 2 further comprises two surrounding, concentrically arranged webs 34 and 35 which are adapted in terms of their distance in the radial
  • the second body part 2 further comprises at least two, preferably four and possibly more, supporting projections 36 for holding the nebulising device 3 (see below) . These are uniformly arranged over the circumference of the second locking body 2 in pairs diametrically opposite one another and, in the case of four elements, each at 90° intervals.
  • the second body part 2 may be designed so as to be
  • the nebulising device 3 comprises the vibratable membrane 37 having a plurality of minute openings or holes (not shown) with diameters in the micrometer range, which completely penetrate the membrane 37.
  • the membrane 37 is vibratable by means of a vibrator 47, such as a piezoelectric element, i.e., the membrane 37 can be caused to oscillate or vibrate by the vibrator 47.
  • the vibrator 47 has an annular shape and is arranged at a peripheral portion of the membrane 37 (see Figs. 4 and 5) .
  • liquid on one side of the membrane 37 i.e., from the liquid chamber 24, will pass through the openings or holes and, on the other side of the membrane 37, is nebulised into a nebulisation chamber 38 formed in the body.
  • This general principle is explained in more detail, for example, in US 5,518,179, and thus a detailed description of this mode of operation will not be provided here.
  • the membrane 37 which is a flat and even element, is held in a frame (not shown) by means of spokes (not shown) .
  • the membrane 37 and the frame are
  • the frame is insert-moulded with a soft resilient material 40, which is the same as or similar to the sealing material 38 and which surrounds the frame as well as parts of its connection 41, shown in Fig. 5, for control and power supply of the nebulising device 3. Except for the spokes along the entire circumference of the membrane, a clearance 42 is formed between the membrane 37 and the radially inner
  • the nebulising device 3 which is pre
  • the nebuliser is supplied ready-assembled and cannot be opened or taken apart.
  • connection 41 such that a sufficient seal is also provided here .
  • the body 1, 2 forms a flow channel from the first connection 10 via connecting piece 11 to the second connection 31 which consists of connecting piece 32, whereby air flows around the nebulising device 3 along flow- around channels 42, 43.
  • the direction of fluid flow into the connecting piece 11 and out of the connecting piece 32 is the same and the membrane 37 and/or the plane in which the membrane 37 lies is arranged perpendicular to this direction of flow or to the central axis of the respective connecting piece 11, 12 or 31.
  • This results in the liquid contained in the liquid container 14 being nebulised through the openings or holes of the membrane 37 into the nebulisation chamber 38 in the direction of flow, i.e. parallel thereto.
  • the design of the present embodiment further allows a bias flow to flow from the air supply line 101 into the air exhaust line 102 via the bypass 13 without passing the nebulising device 3 and, in particular, the nebulisation chamber 38, and thus this bias flow does not flush any aerosol, i.e., nebulised liquid, generated by the nebulising device 3 into the air exhaust line 102 outside of an
  • a unit that is stable against tilting is formed by the three connecting pieces 11, 12 and 32 and the integral connection of the liquid container 14 to the body 1, 2, said tilt-stable unit being beneficial to the flow behaviour of the liquid out of the liquid container 14 into the liquid chamber 24 and up to the membrane 37.
  • the cross-sectional area of the flow-around channel 42 and 43 is configured such that it is not significantly smaller than and is not significantly larger (the latter so as not to create an unnecessarily large dead volume that must be displaced during exhalation by the patient in the case of assisted respiration) than the smallest cross-sectional area in the lines of the assisted breathing device 100 that lead to the patient 800 (line 101 and the connection line via the adapter 104 and the oral and/or nasal communication element) .
  • the nebulising device 3 can be coupled to a control of the assisted breathing device 100 via the connection 41 so as to trigger the nebulising device 3 only in the inhalation cycle. That is to say only when the patient 800 inhales, be it assisted or forced by the assisted breathing device 100, is the membrane 37 vibrated so that nebulisation of the liquid in the liquid container 14 occurs. The efficiency of the system can thereby be increased even further.
  • the flow channel may comprise a tapered portion arranged downstream of the nebulising device 3, wherein, in the tapered portion, the diameter of the flow channel decreases in the direction from the first connection 10 towards the second connection 31. In this way, the efficiency of aerosol transport can be further improved.
  • Fig. 6 shows a perspective view of a nebuliser system
  • the nebuliser system of the embodiment shown in Fig. 6 differs from the nebuliser system of the embodiment shown in Figs. 1 to 5 only in the configuration of the connection to the assisted breathing device 100.
  • connection 10 of the first body part 1 of the nebuliser is composed of a single connecting piece 11.
  • the connecting piece 11 has a bent portion at which it is bent upward by approximately 90°.
  • a connector 105 such as a Y-piece, is coupled, e.g., releasably coupled, to the connecting piece 11.
  • the connector 105 is configured to connect the connecting piece 11 to the air supply line 101 and the air exhaust line 102 of the assisted breathing device 100. Also this
  • nebuliser to be coupled to the tubes of the air supply line 101 and the air exhaust line 102 in a particularly advantageous manner, without significantly impairing accessibility of a patient to be treated or tested.
  • Fig. 7 shows a perspective view of a nebuliser system
  • the nebuliser system shown in Fig. 7 comprises the nebuliser, the adapter 300 (see Figs. 11 and 12), and the nasal
  • communication element 200 can be connected to the nebuliser via the adapter 300.
  • the nebuliser system of the embodiment shown in Fig. 7 differs from the nebuliser system of the embodiment shown in Figs. 1 to 5 only in the configuration of the connection to the assisted breathing device 100.
  • connection 10 of the first body part 1 of the nebuliser is composed of a single connecting piece 11.
  • the connecting piece 11 has a substantially straight shape extending along a longitudinal axis of the nebuliser.
  • a connector 105 is coupled, e.g., releasably coupled, to the connecting piece 11.
  • the connector 105 is configured to connect the connecting piece 11 to the air supply line 101 and the air exhaust line 102 of the artificial respiration machine 100.
  • the connector 105 is substantially in the form of a Y-piece having a bent portion at which it is bent upward by approximately 90°.
  • this arrangement allows for the nebuliser to be coupled to the tubes of the air supply line 101 and the air exhaust line 102 in a particularly advantageous manner, without significantly impairing accessibility of a patient to be treated or tested.
  • Each of the nebulisers of the embodiments described above is configured for being adapted to an oral and/or nasal
  • the nebuliser system of each of the above embodiments comprises an adapter 300, and the adapter 300 is configured for adapting the nebuliser to the nasal communication element 200.
  • Fig. 9 The nebuliser system according to the embodiment shown in Fig. 7, comprising the nebuliser, the adapter 300 and the nasal communication element 200, is shown in Fig. 9.
  • Fig. 10 also shows the adapter 300 and the nasal communication element 200, wherein Fig. 10(a) is a partially exploded perspective view, and Fig. 10(b) is a perspective view showing the adapter 300 and the nasal communication element 200 in the connected state.
  • Figs. 11 and 12 are perspective top and bottom views, respectively, of the adapter 300.
  • the adapter 300 is attached to the body 1, 2 of the
  • the adapter 300 has an attachment portion 302 which is received within the connecting piece 32 of the second connection 31 of the nebuliser (see, for example,
  • the attachment portion 302 has a cylindrical shape with a circular cross-section perpendicular to an axial direction thereof.
  • the adapter 300 is detachably attached to the body 1, 2 and, thus, can be easily replaced.
  • the adapter 300 further has an interface port 304 (see Figs. 10(a) and 11) arranged at the second connection 31 for connecting the nasal communication element 200 to the
  • the interface port 304 is substantially
  • the interface port 304 is in the form of a substantially rectangular recess (see Fig. 11) .
  • the adapter 300 has an adapter flow channel 306 extending through the adapter 300, as is shown in Figs. 11 and 12.
  • the adapter flow channel 306 allows fluid flow from the second connection 31 of the nebuliser to the nasal communication element 200.
  • a portion 308 of the adapter flow channel 306 has an elongate cross-section in a plane perpendicular to the axial direction of the adapter flow channel 306 (see Fig.
  • the elongate portion 308 of the adapter flow channel 306 is arranged partly within the interface port 304.
  • the cross-section of the adapter flow channel 306 varies along the axial direction of the adapter flow channel 306. Specifically, the area of the cross-section of the adapter flow channel 306 decreases in the direction from the second connection 31 to the nasal communication element 200.
  • the shape of the cross-section of the adapter flow channel 306 changes from a substantially circular shape (see Fig. 12) to an elongate shape (see Figs. 11 and 12) in the direction from the second connection 31 to the nasal
  • the adapter 300 has a pair of engagement members 310 for engaging respective communication openings (not shown) of the nasal communication element 200 which will be described in detail below.
  • the engagement members 310 protrude from a bottom surface of the interface port 304.
  • Each of the engagement members 310 has a substantially semi circular shape in a view along the direction of fluid flow through the adapter 300. Further, the engagement members 310 are arranged so as to partly surround an outlet opening 312 of the adapter flow channel 306. Specifically, the engagement members 310 are arranged so as to extend substantially along respective end portions of the outlet opening 312.
  • the nasal communication element 200 can be connected directly to the nebuliser, i.e., to the second connection 31 thereof. Hence, no intermediate
  • the nasal communication element 200 is configured for
  • the nasal communication element 200 is in the form of nasal prongs.
  • Fig. 13 shows an enlarged perspective view of the nasal communication element 200 shown in Figs. 9 and 10.
  • the nasal communication element 200 comprises an interface member 202 (see Figs. 10(a) and 13) for connection to the interface port 304 of the adapter 300.
  • the interface member 202 is
  • the interface member 202 has a substantially rectangular shape in a view along the direction of fluid flow through the interface member 202.
  • the nasal communication element 200 is releasably connected to the adapter 300 by inserting the interface member 202 into the interface port 304 of the adapter 300 (see Fig. 10(b)).
  • the interface member 202 has two communication openings (not shown in Figs. 10(a) and 13; see the communication openings 204 in Figs. 14 and 15(a) to (c) ) for communication with the adapter flow channel 306.
  • the engagement members 310 of the adapter 300 engage these communication openings, so that the nasal communication element 200 is particularly reliably held in its position relative to the adapter 300.
  • the nasal communication element 200 further comprises two fluid guiding members 206 for guiding the aerosol generated by the nebulising device 3 to the patient's nose.
  • the two fluid guiding members 206 are in fluid communication with the interface member 202 through two separate channels (not shown) .
  • Each fluid guiding member 206 is in fluid
  • the nasal communication element 200 has two side flaps 208 arranged at opposing sides thereof. The side flaps 208 allow for the nasal communication element 200 to be held in its position at the patient's nose in a particularly reliable manner, thus further helping to minimise loss of aerosol occurring at the interface between nebuliser and patient .
  • the adapter 300 has a support member 314 in the form of a strap for holding the nasal communication element 200 in position on the patient's head.
  • a modification of the adapter 300 is shown in Figure 22.
  • the modified adapter 300 shown in Figure 22 differs from the adapter 300 shown in Figures 11 and 12 only in that a temperature sensor 316 and an electrical connection 318 of the temperature sensor 316 are provided.
  • the elements which are identical to those of the adapter 300 shown in Figures 11 and 12 are denoted by the same reference signs and a repeated detailed description thereof is omitted.
  • the temperature sensor 316 extends into the flow channel 306 through an opening provided in the attachment portion 302.
  • the electrical connection 318 of the temperature sensor 316 is arranged at an outer surface of the attachment portion 302 for enabling control and power supply of the temperature sensor 316.
  • the electrical connection 318 may be arranged at substantially the same circumferential position as the electrical connection 41 of the nebulising device 3 (see, for example, Figures 1 and 2) . In this way, the nebulising device 3 and the temperature sensor 316 can be electrically
  • the temperature sensor 316 is configured to determine the temperature of a fluid flowing from the second connection 31 of the nebuliser to the nasal communication element 200 (see, for example, Figure 7) . Hence, this temperature can be reliably monitored.
  • the temperature of the fluid flowing through the flow channel 306 can be monitored by means of the temperature sensor 316 and be controlled so as to be in the range of 35°C to 46°C, preferably 36°C to 45°C, more preferably 36°C to 43°C, even more preferably 36°C to 42°C, yet even more preferably 37°C to 39°C and still even more preferably around 37°C. In this way, it can be ensured that the fluid supplied to the patient has the desired temperature.
  • the assisted breathing device 100 and/or the nebuliser may be configured so that fluid supply to the patient is stopped if the
  • the nebuliser may be configured so that the nebulising device 3 is switched off if the temperature determined by the temperature sensor 316 exceeds a threshold value.
  • the threshold value may be, for example, 46°C, 45°C,
  • FIG. 23 A further modification of the adapter 300 is shown in Figure 23.
  • the modified adapter 300 shown in Figure 23 substantially differs from the adapter 300 shown in Figure 22 only in that a wall of the adapter 300 is provided with through-holes for inserting a support member, such as the support member 314 (see Figure 17), as will be further detailed below.
  • a support member such as the support member 314 (see Figure 17)
  • the elements which are identical to those of the adapter 300 shown in Figure 22 are denoted by the same reference signs and a repeated detailed description thereof is omitted.
  • the further modified adapter 300 has two openings 322 through each of which a support member, such as the support member 314 (see Figure 17), can be inserted. As is shown in Figure
  • the two openings 322 are arranged on opposite sides of the adapter 300, in particular, on opposite sides of the interface port 304 (see Figure 11) .
  • Each of the two openings 322 is surrounded by a wall 324 of the adapter 300.
  • the wall 324 is an outer wall of the adapter 300. Such a wall and two such openings are also present in the adapters 300 shown in Figures 11, 12 and 22.
  • the modified adapter 300 shown in Figure 23 differs from the adapters 300 shown in Figures 11, 12 and 22 in that, for each of the two openings 322, the wall 324 of the adapter 300 is provided with a through-hole 326 (see Figure 23) .
  • each through-hole 326 is provided in the form of a slit or slot.
  • Each through-hole 326 is configured to allow insertion of a support member, such as the support member 314, into the respective opening 322 via the
  • the provision of the through-holes 326 allows for the adapter 300 to be attached to an existing support member, e.g., a support member already attached to the patient, in a
  • the through- holes 326 enable simple and efficient attachment of the adapter 300 to a support member in the form of a loop or a lug, e.g., a strap or the like which is in the form of a loop or a lug or which is configured to form a loop or a lug.
  • a support member in the form of a loop or a lug, e.g., a strap or the like which is in the form of a loop or a lug or which is configured to form a loop or a lug.
  • One end of the support member may be attached to the patient, for example, to a cap or hood worn by the patient, and the other end of the support member may be attached to the adapter 300, e.g., by inserting the other end of the support member into the respective opening 322 through the respective through- hole 326.
  • the adapter 300 shown in Figure 23 further comprises a connection element 320 for connecting a temperature sensor, such as the temperature sensor 316 (see Figure 22), to the adapter 300.
  • a temperature sensor such as the temperature sensor 316 (see Figure 22)
  • the connection element 320 enables attachment of the temperature sensor to the adapter 300 so that the temperature sensor extends into the flow channel 306 through an opening provided in the attachment portion 302 (see Figure 23) .
  • the temperature sensor may be provided with a sealing component which is configured to seal this opening upon attachment of the temperature sensor to the adapter 300.
  • connection element 320 has two opposing recesses or grooves, one of which is shown in Figure 23. These recesses or grooves may be configured for receiving corresponding protrusions of the temperature sensor. In this way, it can be reliably ensured that the temperature sensor is attached to the adapter 300 with a defined angular alignment between temperature sensor and adapter 300. This is particularly beneficial if the temperature sensor has a measuring
  • connection element 320 and the
  • temperature sensor may be configured so that the temperature sensor can be attached to the adapter 300, for example, by snap fit or friction fit.
  • connection element 320 may have more than two recesses or grooves.
  • connection element 320 of the adapter 300 shown in Figure 24 has four recesses or grooves which are substantially equidistantly spaced along a
  • connection element 320 circumference of the connection element 320. Also the
  • connection element 320 of the adapter 300 shown in Figure 23 may have four recesses or grooves which are substantially equidistantly spaced along a circumference of the connection element 320. This at least one recess (or groove) may ensure an especially accurate alignment and/or fixed orientation of the temperature sensor 316 in an attached position on the connection element 320.
  • FIG. 24 A further modification of the adapter 300 is shown in Figure 24.
  • the modified adapter 300 shown in Figure 24 substantially differs from the adapter 300 shown in Figure 23 only in that, instead of the through-holes 326, a pair of protrusions 328 is provided, as will be further detailed below.
  • the elements which are identical to those of the adapter 300 shown in Figure 23 are denoted by the same reference signs and a repeated detailed description thereof is omitted.
  • the two protrusions 328 are arranged on opposite sides of the adapter 300. Each of the two protrusions 328 is disposed next to a respective one of the two openings 322. In the
  • protrusions 328 is shown.
  • the protrusions 328 are in the form of engagement members, in particular, hook members.
  • Each of the protrusions 328 is configured for engagement with a support member, such as the support member 314 (see Figure 17) .
  • the provision of the protrusions 328 allows for the adapter 300 to be attached to an existing support member, e.g., a support member already attached to the patient, in a
  • protrusions 328 enable simple and efficient attachment of the adapter 300 to a support member having, e.g., at one of its ends, an engagement portion, such as an eye, a loop or a bail, for engagement with the protrusion 328.
  • the one end of the support member may be attached to the adapter 300 by engaging the engagement portion with the protrusion 328 and the other end of the support member may be attached to the patient, for example, to a cap or hood worn by the patient.
  • the support member may be attached to the adapter 300 by means of the protrusion 328.
  • protruding portions 330 protrude or project from a side or surface of the adapter 300 which is opposite to the side or surface of the adapter 300 at which the attachment portion 302 is provided (see Figure 24) .
  • the protruding portions 330 are inclined relative to the side or surface of the adapter 300 from which they protrude or project, as is shown in Figure 24.
  • Each of the protruding portions 330 offers an abutment, e.g., an abutment surface, for a
  • nasal communication elements 200 are shown in Figs. 14 and 15(a) to (c) .
  • the general configuration of these nasal communication elements 200 is substantially the same as that of the nasal communication element 200 shown in Figs. 9, 10(a), 10(b) and 13. Hence, the same reference signs are used to denote identical or similar components.
  • Each of the of nasal communication elements 200 shown in Figs. 14 and 15(a) to (c) has a substantially rectangular interface member 202, two communication openings 204 and two fluid guiding members 206.
  • the nasal communication elements 200 shown in Figs. 14 and 15(a) to (c) mainly differ from the nasal communication element 200 shown in Figs. 9, 10(a) and 10 (b) in the shape and the arrangement of the two fluid guiding members 206.
  • the nasal communication elements 200 shown in Figs. 14 and 15 (a) to (c) differ from each other in the size and the arrangement of the two communication openings 204 and the two fluid guiding members 206.
  • the nasal communication element 200 to be used for aerosol treatment can be suitably chosen depending on the anatomy of the patient 800 to be treated.
  • the nasal communication element 200 of Fig. 15(c) may be used for treating a neonate.
  • the nebuliser system can be readily adapted to the requirements of the patient 800.
  • the adapter 300 and/or the nasal communication element 200 may be made of plastic.
  • the adapter 300 and/or the nasal communication element 200 may be produced in an injection moulding process.
  • Fig. 16 shows a partially exploded perspective view of a holding system 400 according to an embodiment of the present invention.
  • the holding system 400 is configured for holding the nebuliser system shown in Fig. 9.
  • the holding system 400 comprises a base 402, a holding arm 404 extending from the base 402, and a holding element 406 configured to hold the nebuliser system.
  • the holding arm 404 has a first end 408 and a second end 410 opposite to the first end 408.
  • the first end 408 of the holding arm 404 is attached to the base 402.
  • the holding element 406 is attached to the holding arm 404 at the second end 410 of the holding arm 404.
  • the base 402 and/or the holding arm 404 and/or the holding element 406 may be made of a metal.
  • the holding system 400 allows for the nebuliser system to be stably held in its position (see Fig. 17), so that efficient aerosol transport from the nebuliser to the patient 800 can be secured and reliably maintained. Hence, aerosol therapy can be performed with a high degree of efficiency and
  • the first end 408 of the holding arm 404 is detachably attached to the base 402, as is indicated by an arrow in Fig. 16, allowing for the holding arm 404 to be replaced in a simple manner.
  • the holding element 406 is detachably attached to the holding arm 404 at the second end 410 of the holding arm 404. In both cases, the detachable attachment is effected by a clamping screw, i.e., the clamping screw 412 and the clamping screw 414, respectively.
  • the base 402 has a curved shape, namely a U-shape, allowing for a particularly secure and stable placement of the holding system 400 on a placement surface (see Fig. 17) .
  • the holding arm 404 is flexible. Specifically, the holding arm 404 is configured so that it can be substantially freely bent into a desired shape and subsequently maintains this shape. Thus, the holding system 400 can be easily and
  • the holding arm 404 has a length in the range of 20 cm to 50 cm, ensuring good accessibility of the patient 800 and, at the same time, a robust arrangement of the holding system 400.
  • the holding element 406 has a plurality of holding portions 416, i.e., three holding portions 416.
  • Each holding portion 416 is configured for holding a component of the nebuliser system, in particular, a tube, a pipe or a line of the nebuliser system (see Fig. 17) .
  • Each of the holding portions 416 is in the form of a recess or cut-out configured for partly receiving therein tubes, pipes or lines of the
  • Fig. 17 shows a perspective view of a combination according to an embodiment of the present invention, comprising the nebuliser system of Fig. 9 and the holding system of Fig. 16.
  • Fig. 17 shows the combination in a state in which it is being used for treating a neonate as the patient 800.
  • the nasal communication element 200 is
  • Tubes 500 of the nebuliser system connecting the connecting pieces 11, 12 of the nebuliser to the air supply line 101 and the air exhaust line 102 of the assisted breathing device 100, respectively, are held by respective holding portions 416 and guided over the holding element 406, so that the patient 800 remains readily accessible, as is shown in Fig. 17.
  • this accessibility of the patient 800 is achieved by the holding arm 404, allowing for the holding element 406 to be arranged in separation from the base 402.
  • the holding system 400 also securely holds the nebuliser.
  • an embodiment of the method of the invention of administering an aerosol to a patient can be performed.
  • an aerosol may be generated by nebulising the liquid received in the liquid container 14 by means of the nebulising device 3. Subsequently, the aerosol thus generated may be supplied to the patient 800 through the second
  • connection 31 of the nebuliser, the adapter 300 and the nasal communication element 200 In this manner, a particularly efficient aerosol treatment can be carried out.
  • Example 1 The study of Example 1 was carried out in newborn piglets between days 2-4 of life with lung injury and surfactant deficiency induced by repeated saline lavage (BAL) (Lachmann B et al . Acta Anaesthesiol Scand 1980; 24:231-236).
  • BAL repeated saline lavage
  • Piglets 2 to 4-d old were sedated with i.m. ketamine (15 mg/kg) -diazepam (2 mg/kg)- atropine (0.05 mg7kg) injection and were anesthetised with sevofluorane (2-3%) .
  • a tracheal tube (4.0 mmID) was inserted and connected to positive pressure ventilator (VIP Bird, Bird Products Corp., Palm Springs, CA) with the following initial settings:
  • Surfactant-deficient lung injury was achieved by repetitive saline lavage (30 ml/kg; 37°C with FI02 : 1) via endotracheal tube. Lavage procedures were repeated at 5 minutes interval until Pa02 ⁇ 100 mmHg for a period of 30 minute (BAL point,
  • nCPAP group newborn piglets with surfactant- deficient lung injury received a 200 mg/kg of Curosurf® using Insure technique. With the animal in supine position, the Curosurf® bolus was administered in about one min without ventilator disconnection. After surfactant administration newborn piglets were maintained in nCPAP during 180 min.
  • nCPAP + Neb 100 group newborn piglets with surfactant- deficient lung injury received 100 mg/kg of nebulised
  • the animals were positioned in supine position during the experimental period and maintained in nCPAP during 180 min.
  • A-a oxygen tension difference
  • a/AD02 arterial/alveolar oxygen ratio
  • A-aD02 PA02-Pa02; where PA02 is alveolar concentration of oxygen. It is used in diagnosing the source of hypoxemia.
  • a/AD02 Pa02/Pi02- (PaC02/R) ; where R, the respiratory exchange quotient, was assumed to be 0.8. This parameter is frequently used to evaluate impairment of oxygenation.
  • VEI [3800/ (PIP/PEEP) *respiratory frequency *PaC02]. VEI scores decrease as pulmonary function impairs; it is used as an index of C02 elimination efficiency.
  • MAP 01 [mean airway pressure (MAP) *FI02/Pa02 ] . This is felt to be a more sensitive indicator for severity of pulmonary illness as MAP is taken into its calculation.
  • lung injury score and lung biochemical analysis as a function of group. Comparisons of results (gas exchange, ventilatory parameters) were performed by repeated measures two-way ANOVA as a function of group and time. A p-value of 0.05 was accepted as significant.
  • Fig. 18 shows mean A-aD02 ratio values in nCPAP, Insure+nCPAP, nCPAP+Neb600 , nCPAP+Neb400 and
  • nCPAP+Neb200 groups Mean and SEM are shown: * Vs. nCPAP and # Vs. Insure groups; single-factor ANOVA. $ Vs. nCPAP and & Vs. Insure group; two-factor ANOVA (along the time) .
  • Fig. 19 shows mean FI02 values in nCPAP, Insure+nCPAP, nCPAP+Neb600 , nCPAP+Neb400 and nCPAP+Neb200 groups. Mean and SD are shown: * Vs. nCPAP and # Vs. Insure groups; single factor ANOVA. $ Vs. nCPAP and & Vs. Insure group; two- factor ANOVA (along the time) .
  • Pa02/Fi02 and a/AD02 ratio showed a significant improvement in Insure group
  • nCPAP+Neb200 and nCPAP+Neb400 groups in comparison with nCPAP group, while A-aD02 values rapidly decreased.
  • Fi02 was rapidly reduced in Insure and nCPAP+Neb400 groups compared to nCPAP group (see Fig. 19) . Although Fi02 was also reduced in nCPAP+Neb200 and nCPAP+Neb600 groups, it was not as quick as in Insure group. Moreover, Fi02 in nCPAP+NeblOO group could not be reduced in comparison with nCPAP group.
  • a new way of surfactant administration using a vibrating membrane nebuliser system (investigational eFlow Neonatal System, Pari Pharma, Kunststoff, Germany) , was administered to newborn piglets with surfactant-deficient lung injury using four different administration doses (100 mg/kg, 200 mg/kg,
  • the biochemical analysis of the lung reported a significant reduction of catalase activity and TNF-alpha factor in nebulised groups compared with nCPAP and Insure treatment. Moreover, although all nebulised treated groups demonstrated a significant reduction of lung injury score in comparison with nCPAP treatment, showing Neb 400 and Neb 600 groups lower lung injury score than nCPAP+Insure group.
  • the nebuliser was positioned between the nasal prongs (Fisher & Paykel Healthcare, nasal prongs 3520) and the Y-piece of the CPAP circuit.
  • the prongs were connected directly to the nebuliser through a PARI custom made adapter.
  • Rabbits (body weight of 1.5-2.5 kg) were sedated with medetomidine (Domitor®) 2 mg/kg intramuscolarly (i.m.) and local anaesthesia was performed with lidocaine gel (Luan 1%®) in the anterior neck, after having shaved the throat. Thirty minutes after sedation, the animals received 50 mg/kg of ketamine (Imalgene®) and 5 mg/kg of xylazine i.m. Rabbits, in supine position, were intubated and stabilised on positive pressure ventilation (Acutronic Fabian HFO) with the
  • RR 40 breaths/min
  • PEEP positive end- expiratory pressure
  • BALs were performed by flushing the airways with 30 ml of pre-warmed 0.9% NaCl solution, followed by a short recovery period in-between, until a Pa02 value ⁇ 150mmHg was reached. Then, if after 15 min of stabilisation in mechanical ventilation the respiratory failure was re-confirmed with a new blood gas analysis (stabilisation period; 15ST) , the animal was extubated and managed by nCPAP, using Fisher & Paykel nasal prongs. Once spontaneous breathing was
  • nCPAP rabbits with surfactant deficiency induced by BALs were maintained in nCPAP for 180 minutes. In this group, the nebuliser was placed in the circuit for 30 minutes without surfactant treatment. This group works as "negative control group" in this experiment.
  • Curosurf® bolus was administered in about one minute. After surfactant administration animals were maintained in nCPAP for 180 minutes. This group works as "positive control group" in this experiment.
  • Fig. 20 shows blood oxygenation values in the lavage (0; -15 minutes pre-treatment), stabilisation
  • Pa02 values in all treatment groups were significantly different in comparison with negative control group (*p ⁇ 0.01); Pa02 values in the 100 mg/kg group were significantly different compared to Insure 200mg/kg group ( ⁇ p ⁇ 0.05).
  • Pa02 values showed a rapid improvement in InSurE, 200, 400 and 600 mg/kg treated groups. After 120 minutes, all these groups showed Pa02 values that were significantly higher in comparison with the nCPAP-treated negative control group. The improvement was mild and slow in the 100 mg/kg group, which at two hours post treatment had significantly lower values than the InSurE group and not significantly different from the nCPAP group. Untreated animals (negative control) did not recover and their
  • oxygenation values were unchanged (-100 mmHg) despite nCPAP support (see Fig. 20) .
  • FIG. 21 shows that the pressure P (cmH20) measured at maximal volume, i.e., a volume of 30 ml, was significantly lower in the InSurE, 200 and 400 mg/kg groups as compared to the negative control group (*p ⁇ 0.05) .
  • P cmH20
  • the study was carried out in adult rabbits (6-7 week old) with surfactant deficiency induced by repeated BALs with saline.
  • BALs induced a significant worsening of the overall lung function including gas
  • nCPAP was established at 5 cmH20.
  • Curosurf® was administered by nebulisation using a new vibrating membrane nebuliser (investigational eFlow Neonatal System, Pari Pharma, Kunststoff, Germany) .
  • Curosurf® 100 mg/kg, 200 mg/kg, 400 mg/kg or 600 mg/kg administered by nebulisation were tested. The results from these groups were compared with two well-established clinical treatments: surfactant administration using the InSurE technique and nCPAP (no surfactant) treatment.
  • nebulised surfactant 200 and 400 mg/kg

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un système de nébuliseur comprenant un nébuliseur pour des dispositifs respiratoires assistés, tels que des dispositifs de pression expiratoire positive continue (CPAP). Le nébuliseur comprend un corps (1, 2) avec un premier raccord (10) pour raccorder le nébuliseur à un dispositif respiratoire assisté (100) et un deuxième raccord (31) pour raccorder le nébuliseur à un patient (800), en particulier un nouveau-né, le corps (1, 2) formant un canal d'écoulement du premier raccord (10) au deuxième raccord (31), et un dispositif de nébulisation (3) pour nébuliser un liquide. Le dispositif de nébulisation (3) est disposé dans le canal d'écoulement entre le premier raccord (10) et le deuxième raccord (31). Le nébuliseur est conçu pour être adapté à un élément de communication oral et/ou nasal (200), tel que des canules nasales, un masque nasal, un masque facial ou un embout buccal. L'élément de communication oral et/ou nasal (200) est configuré pour établir une communication fluidique entre le nébuliseur et le nez et/ou la bouche d'un patient. L'invention concerne également un procédé d'administration d'un aérosol à un patient (800) à l'aide de ce système nébuliseur. En outre, l'invention concerne un système de maintien (400) pour maintenir un nébuliseur ou un système de nébuliseur et une combinaison comprenant un tel système de nébuliseur et un tel système de maintien (400).
PCT/EP2018/084968 2017-12-15 2018-12-14 Système de nébuliseur, système de maintien, combinaison comprenant un système de nébuliseur et un système de maintien, et procédé d'administration d'aérosol WO2019115771A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17207666 2017-12-15
EP17207666.3 2017-12-15

Publications (1)

Publication Number Publication Date
WO2019115771A1 true WO2019115771A1 (fr) 2019-06-20

Family

ID=60673683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/084968 WO2019115771A1 (fr) 2017-12-15 2018-12-14 Système de nébuliseur, système de maintien, combinaison comprenant un système de nébuliseur et un système de maintien, et procédé d'administration d'aérosol

Country Status (1)

Country Link
WO (1) WO2019115771A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243106A1 (fr) * 2019-05-24 2020-12-03 Stamford Devices Ltd. Conception de chambre d'aérosol et interface pour optimiser une dose inhalée avec un dispositif de cpap néonatal
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
EP3843105A1 (fr) * 2019-12-23 2021-06-30 PARI Pharma GmbH Dispositif de commande pour système nébuliseur d'aérosol
WO2021198116A1 (fr) 2020-04-01 2021-10-07 UNION therapeutics A/S Formulation
WO2021198115A1 (fr) 2020-04-01 2021-10-07 UNION therapeutics A/S Traitement
CN113751267A (zh) * 2021-09-14 2021-12-07 天津大学 一种水雾定量生成和控制装置
IL275477A (en) * 2020-06-17 2022-01-01 Uri Haimi Shlomo Device and method for use in the treatment of pathogens
WO2022157004A1 (fr) * 2021-01-22 2022-07-28 Löwenstein Medical Technology S.A. Dispositif de mesure pour analyser un flux de gaz respiratoire
EP4374903A1 (fr) 2022-11-24 2024-05-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Administration d'un aérosol à un patient
EP4353288A3 (fr) * 2019-09-26 2024-06-19 Vapotherm, Inc. Nébuliseur monté sur une canule interne

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156409A2 (fr) * 1984-02-23 1985-10-02 Jean Michel Anthony Dispositif pour humidifier localement le corps humain
WO1989006657A1 (fr) 1988-01-06 1989-07-27 Scripps Clinic And Research Foundation Proteine de tensio-actif pulmonaire et polypeptide s'y rapportant
WO1992022315A1 (fr) 1991-06-14 1992-12-23 The Scripps Research Institute Peptides tensioactifs pulmonaires synthetiques
WO1995032992A1 (fr) 1994-05-31 1995-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Analogues peptidiques de synthese de la proteine sp-c de surfactant
US5518179A (en) 1991-12-04 1996-05-21 The Technology Partnership Limited Fluid droplets production apparatus and method
WO2000047623A1 (fr) 1999-02-12 2000-08-17 Chiesi Farmaceutici S.P.A. Peptides artificiels ayant une activite de surface et utilisation de ceux-ci dans la preparation d'un tensioactif artificiel
DE10122065A1 (de) 2001-05-07 2002-12-12 Pari Gmbh Vorrichtung zur Erzeugung von Flüssigkeitströpfchen mit einer in Schwingungen versetzten Membran
US20030072717A1 (en) 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
US20040244804A1 (en) * 2001-09-13 2004-12-09 Olsen Gregory James Breathing assistance apparatus
WO2005048982A2 (fr) 2003-11-17 2005-06-02 Nektar Therapeutics Systeme d'introduction d'aerosol dans un circuit de ventilateur
WO2005102431A2 (fr) * 2004-04-20 2005-11-03 Aerogen, Inc. Appareil d'administration en aerosol, methodes et compositions pour systemes de respiration assistee en pression
WO2006026237A1 (fr) * 2004-05-20 2006-03-09 Discovery Laboratories, Inc. Procédés, systèmes et dispositifs d’administration pulmonaire non-invasive
WO2007020073A1 (fr) 2005-08-16 2007-02-22 Pari Pharma Gmbh Dispositif de therapie par inhalation pourvu d'une ampoule destinee a contenir un medicament a nebuliser
WO2007064658A2 (fr) * 2005-11-30 2007-06-07 Transave, Inc. Procedes efficaces et sans risques d'administation d'agents therapeutiques
EP1818070A2 (fr) 2006-02-10 2007-08-15 Pari GmbH Dispositif de thérapie par inhalation à utiliser par des prématurés et des enfants en bas âge
US20080236588A1 (en) * 2007-03-26 2008-10-02 Braebon Medical Corporation Support device for respiratory interface
WO2010035251A2 (fr) * 2008-09-26 2010-04-01 Stamford Devices Limited Système de distribution d’oxygène supplémentaire
WO2010091259A2 (fr) * 2009-02-06 2010-08-12 Vapotherm, Inc. Nébuliseurs chauffés, systèmes de nébuliseur, et procédés d'inhalothérapie
WO2010097119A1 (fr) * 2009-02-27 2010-09-02 Pari GmbH Spezialisten für effektive Inhalation Procédé d'actionnement d'un dispositif d'inhalation sous forme d'aérosol, et dispositif d'inhalation sous forme d'aérosol
WO2010139442A1 (fr) 2009-06-05 2010-12-09 Chiesi Farmaceutici S.P.A. Composition de surfactant reconstitué améliorée contenant des analogues de la protéine b du surfactant (sp-b) et de la protéine c du surfactant (sp-c)
US20110283996A1 (en) * 2007-09-18 2011-11-24 Robert Abrams Enhanced semi-automatic emergency medication dose nebulizer
US20130174840A1 (en) * 2008-05-09 2013-07-11 Pari Pharma Gmbh Nebuliser for ventilation machines and a ventilation machine comprising such a nebuliser
US20130306060A1 (en) * 2012-05-15 2013-11-21 JettStream, Inc. Delivery of Nebulized Medicines
US9168556B2 (en) 2009-06-02 2015-10-27 Pari Pharma Gmbh Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer
WO2016043604A1 (fr) * 2014-09-17 2016-03-24 Fisher & Paykel Healthcare Limited Connecteurs pour des systèmes d'assistance respiratoire
EP3037120A1 (fr) * 2014-12-23 2016-06-29 PARI Pharma GmbH Dispositif de livraison d'aérosol et procédé de fonctionnement d'un tel dispositif
WO2017059292A1 (fr) * 2015-10-01 2017-04-06 Fukunaga Atsuo F Systèmes et méthodes de réanimation, de ventilation assistée et d'anesthésie

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156409A2 (fr) * 1984-02-23 1985-10-02 Jean Michel Anthony Dispositif pour humidifier localement le corps humain
WO1989006657A1 (fr) 1988-01-06 1989-07-27 Scripps Clinic And Research Foundation Proteine de tensio-actif pulmonaire et polypeptide s'y rapportant
WO1992022315A1 (fr) 1991-06-14 1992-12-23 The Scripps Research Institute Peptides tensioactifs pulmonaires synthetiques
US5518179A (en) 1991-12-04 1996-05-21 The Technology Partnership Limited Fluid droplets production apparatus and method
WO1995032992A1 (fr) 1994-05-31 1995-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Analogues peptidiques de synthese de la proteine sp-c de surfactant
WO2000047623A1 (fr) 1999-02-12 2000-08-17 Chiesi Farmaceutici S.P.A. Peptides artificiels ayant une activite de surface et utilisation de ceux-ci dans la preparation d'un tensioactif artificiel
US20030072717A1 (en) 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
DE10122065A1 (de) 2001-05-07 2002-12-12 Pari Gmbh Vorrichtung zur Erzeugung von Flüssigkeitströpfchen mit einer in Schwingungen versetzten Membran
US20040244804A1 (en) * 2001-09-13 2004-12-09 Olsen Gregory James Breathing assistance apparatus
WO2005048982A2 (fr) 2003-11-17 2005-06-02 Nektar Therapeutics Systeme d'introduction d'aerosol dans un circuit de ventilateur
WO2005102431A2 (fr) * 2004-04-20 2005-11-03 Aerogen, Inc. Appareil d'administration en aerosol, methodes et compositions pour systemes de respiration assistee en pression
WO2006026237A1 (fr) * 2004-05-20 2006-03-09 Discovery Laboratories, Inc. Procédés, systèmes et dispositifs d’administration pulmonaire non-invasive
WO2007020073A1 (fr) 2005-08-16 2007-02-22 Pari Pharma Gmbh Dispositif de therapie par inhalation pourvu d'une ampoule destinee a contenir un medicament a nebuliser
WO2007064658A2 (fr) * 2005-11-30 2007-06-07 Transave, Inc. Procedes efficaces et sans risques d'administation d'agents therapeutiques
EP1818070A2 (fr) 2006-02-10 2007-08-15 Pari GmbH Dispositif de thérapie par inhalation à utiliser par des prématurés et des enfants en bas âge
US20080236588A1 (en) * 2007-03-26 2008-10-02 Braebon Medical Corporation Support device for respiratory interface
US20110283996A1 (en) * 2007-09-18 2011-11-24 Robert Abrams Enhanced semi-automatic emergency medication dose nebulizer
US20130174840A1 (en) * 2008-05-09 2013-07-11 Pari Pharma Gmbh Nebuliser for ventilation machines and a ventilation machine comprising such a nebuliser
WO2010035251A2 (fr) * 2008-09-26 2010-04-01 Stamford Devices Limited Système de distribution d’oxygène supplémentaire
WO2010091259A2 (fr) * 2009-02-06 2010-08-12 Vapotherm, Inc. Nébuliseurs chauffés, systèmes de nébuliseur, et procédés d'inhalothérapie
WO2010097119A1 (fr) * 2009-02-27 2010-09-02 Pari GmbH Spezialisten für effektive Inhalation Procédé d'actionnement d'un dispositif d'inhalation sous forme d'aérosol, et dispositif d'inhalation sous forme d'aérosol
US9168556B2 (en) 2009-06-02 2015-10-27 Pari Pharma Gmbh Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer
WO2010139442A1 (fr) 2009-06-05 2010-12-09 Chiesi Farmaceutici S.P.A. Composition de surfactant reconstitué améliorée contenant des analogues de la protéine b du surfactant (sp-b) et de la protéine c du surfactant (sp-c)
US20130306060A1 (en) * 2012-05-15 2013-11-21 JettStream, Inc. Delivery of Nebulized Medicines
WO2016043604A1 (fr) * 2014-09-17 2016-03-24 Fisher & Paykel Healthcare Limited Connecteurs pour des systèmes d'assistance respiratoire
EP3037120A1 (fr) * 2014-12-23 2016-06-29 PARI Pharma GmbH Dispositif de livraison d'aérosol et procédé de fonctionnement d'un tel dispositif
WO2017059292A1 (fr) * 2015-10-01 2017-04-06 Fukunaga Atsuo F Systèmes et méthodes de réanimation, de ventilation assistée et d'anesthésie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H. VERDER; B. ROBERTSON; G. GREISEN ET AL.: "Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome", NEW ENGLAND JOURNAL OF MEDICINE, vol. 331, no. 16, 1994, pages 1051 - 1055, XP001005599, DOI: doi:10.1056/NEJM199410203311603
LACHMANN B ET AL., ACTA ANAESTHESIOL SCAND, vol. 24, 1980, pages 231 - 236

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243106A1 (fr) * 2019-05-24 2020-12-03 Stamford Devices Ltd. Conception de chambre d'aérosol et interface pour optimiser une dose inhalée avec un dispositif de cpap néonatal
EP4353288A3 (fr) * 2019-09-26 2024-06-19 Vapotherm, Inc. Nébuliseur monté sur une canule interne
EP3843105A1 (fr) * 2019-12-23 2021-06-30 PARI Pharma GmbH Dispositif de commande pour système nébuliseur d'aérosol
WO2021130213A1 (fr) * 2019-12-23 2021-07-01 Pari Pharma Gmbh Dispositif de commande pour système de nébuliseur d'aérosol
US11324708B1 (en) 2020-04-01 2022-05-10 UNION therapeutics A/S Niclosamide formulations for treating disease
WO2021198115A1 (fr) 2020-04-01 2021-10-07 UNION therapeutics A/S Traitement
WO2021198116A1 (fr) 2020-04-01 2021-10-07 UNION therapeutics A/S Formulation
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
IL275477A (en) * 2020-06-17 2022-01-01 Uri Haimi Shlomo Device and method for use in the treatment of pathogens
WO2022157004A1 (fr) * 2021-01-22 2022-07-28 Löwenstein Medical Technology S.A. Dispositif de mesure pour analyser un flux de gaz respiratoire
CN113751267A (zh) * 2021-09-14 2021-12-07 天津大学 一种水雾定量生成和控制装置
CN113751267B (zh) * 2021-09-14 2022-04-19 天津大学 一种水雾定量生成和控制装置
EP4374903A1 (fr) 2022-11-24 2024-05-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Administration d'un aérosol à un patient
WO2024110588A1 (fr) 2022-11-24 2024-05-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Administration d'un aérosol à un patient

Similar Documents

Publication Publication Date Title
WO2019115771A1 (fr) Système de nébuliseur, système de maintien, combinaison comprenant un système de nébuliseur et un système de maintien, et procédé d'administration d'aérosol
US9687627B2 (en) Nebuliser for ventilation machines and a ventilation machine comprising such a nebuliser
CA2753645C (fr) Procede d'actionnement d'un dispositif d'inhalation sous forme d'aerosol, et dispositif d'inhalation sous forme d'aerosol
US20230119086A1 (en) Aerosol delivery device and operating method for the aerosol delivery device
US10426909B2 (en) Nasal respiratory assembly and methods of use
TW201927286A (zh) 用於噴霧投藥之包含肺表面張力素的藥學調配物
EP2938381B1 (fr) Ensemble respiratoire nasal
ES2971119T3 (es) Dispositivo de administración de aerosol y método de hacer funcionar el dispositivo de administración de aerosol
AU2015264908B2 (en) Nebuliser for Ventilation Machines and a Ventilation Machine Comprising such a Nebuliser
EP3893970B1 (fr) Dispositif d'administration d'aérosol et procédé pour faire fonctionner un dispositif d'administration d'aérosol
US20230028709A1 (en) Control device for aerosol nebulizer system
AU2013201359B2 (en) Atomizer for Ventilation Machines and Ventilation Machine Comprising said Atomizer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18815239

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18815239

Country of ref document: EP

Kind code of ref document: A1